10-Q 1 aebf_10q.htm QUARTERLY REPORT UNITED STATES


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


———————

FORM 10-Q

———————


þ   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2009

or

¨   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from: _____________ to _____________

Commission File Number: 00-51354

———————

AE BIOFUELS, INC.

 (Exact name of registrant as specified in its charter)

———————


Nevada

26-1407544

(State or other jurisdiction

(I.R.S. Employer

of incorporation or organization)

Identification No.)


20400 Stevens Creek Blvd., Suite 700

Cupertino, CA 95014

 (Address of Principal Executive Office) (Zip Code)


(408) 213-0940

 (Registrant’s telephone number, including area code)

———————

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such filed).   Yes  þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨     Accelerated filer  þ     Non-accelerated filer  ¨     Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ¨ No þ

The number of shares outstanding of the registrant’s Common Stock on November 3, 2009 was 86,181,532.


 

 







AE BIOFUELS, INC.

FORM 10-Q

Quarterly Period Ended September 30, 2009

INDEX


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

PART I.--FINANCIAL INFORMATION

Item 1.        Financial Statements

1

Item 2.        Management's Discussion and Analysis of Financial Condition and Results of Operations

22

Item 3.        Quantitative and Qualitative Disclosures about Market Risk

36

Item 4.        Controls and Procedures

37

PART II--OTHER INFORMATION

Item 1.        Legal Proceedings

38

Item 1A.     Risk Factors

38

Item 2.        Unregistered Sales of Equity Securities and Use of Proceeds

38

Item 3.        Defaults On Senior Securities

38

Item 4.        Submission of Matters to a Vote of Security Holders

38

Item 5.        Other Information

38

Item 6.        Exhibits

39

SIGNATURES

40



i



SPECIAL NOTE REGARDING FORWARD—LOOKING STATEMENTS

On one or more occasions, we may make forward-looking statements in this Quarterly Report on Form 10-Q regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events. Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “targets,” “will likely result,” “will continue” or similar expressions identify forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those identified below, under “Part II — Other Information, Item 1A. Risk Factors” and elsewhere, and in other reports we file with the Securities and Exchange Commission (“SEC”), specifically our most recent Annual Report on Form 10-K and 10-K/A. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. However, your attention is directed to any further disclosures made on related subjects in our subsequent annual and periodic reports filed with the SEC on Forms 10-K, 10-Q and 8-K and Proxy Statements on Schedule 14A.

Unless the context requires otherwise, references to “we,” “us,” “our,” the “Company” and “the Company” refer specifically to AE Biofuels, Inc.



ii



PART I - FINANCIAL INFORMATION

Item 1 - Financial Statements.

AE BIOFUELS, INC.

CONSOLIDATED BALANCE SHEETS


 

 

September 30,
2009

 

 

December 31,
2008

 

 

 

(Unaudited)

 

 

 

 

Assets

  

                       

 

  

                       

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

107,631

 

 

$

377,905

 

Inventories

 

 

818,536

 

 

 

1,049,583

 

Prepaid expenses

 

 

21,901

 

 

 

110,581

 

Other current assets

 

 

534,558

 

 

 

438,703

 

Total current assets

 

 

1,482,626

 

 

 

1,976,772

 

  

 

 

 

 

 

 

 

 

Property, plant and equipment, net

 

 

18,239,779

 

 

 

21,236,604

 

Intangible assets

 

 

––

 

 

 

33,333

 

Other assets

 

 

38,600

 

 

 

289,990

 

Total assets

 

$

19,761,005

 

 

$

23,536,699

 

  

 

 

 

 

 

 

 

 

Liabilities and stockholders' (deficit) equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

3,574,672

 

 

$

2,829,117

 

Short term borrowings, net of discount

 

 

6,242,265

 

 

 

4,504,062

 

Registration rights liability

 

 

-

 

 

 

1,807,748

 

Mandatorily redeemable Series B Preferred stock

 

 

1,750,002

 

 

 

1,750,002

 

Other current liabilities

 

 

2,109,132

 

 

 

1,616,259

 

Current portion of long term debt

 

 

4,084,013

 

 

 

816,738

 

Current portion of long term debt (related party)

 

 

3,650,819

 

 

 

––

 

Total current liabilities

 

 

21,410,903

 

 

 

13,323,926

 

  

 

 

 

 

 

 

 

 

Long term debt, net of discount

 

 

––

 

 

 

3,174,275

 

Long term debt (related party)

 

 

––

 

 

 

2,044,691

 

  

 

 

 

 

 

 

 

 

Commitments and contingencies (Notes 2,4,7,8,9,14,16 and 18 )

 

 

 

 

 

 

 

 

Stockholders' (deficit) equity:

 

 

 

 

 

 

 

 

AE Biofuels, Inc. stockholders (deficit) equity

 

 

 

 

 

 

 

 

Series B Preferred Stock - $.001 par value - 7,235,565 authorized; 3,330,725 and 3,451,892 shares issued and outstanding, respectively (aggregate liquidation preference of $9,992,175 and $10,355,676, respectively)

 

 

3,331

 

 

 

3,452

 

Common Stock - $.001 par value 400,000,000 authorized; 86,171,532 and 85,643,709 shares issued and outstanding, respectively

 

 

86,171

 

 

 

85,643

 

Additional paid-in capital

 

 

36,652,175

 

 

 

34,238,925

 

Accumulated deficit

 

 

(36,310,127

)

 

 

(27,831,340

)

Accumulated other comprehensive income

 

 

(1,787,557

)

 

 

(1,502,873

)

Total AE Biofuels, Inc. stockholders (deficit) equity

 

 

(1,356,007

)

 

 

4,993,807

 

Noncontrolling interest

 

 

(293,891

)

 

 

––

 

Total stockholders' (deficit) equity

 

 

(1,649,898

)

 

 

4,993,807

 

Total liabilities and stockholders' (deficit) equity

 

$

19,761,005

 

 

$

23,536,699

 



The accompanying notes are an integral part of the financial statements

1



AE BIOFUELS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


 

 

For the nine months ended

 

 

For the three months ended

 

 

 

September 30, 2009

 

 

September 30, 2008

 

 

September 30, 2009

 

 

September 30, 2008

 

Sales 

  

$

7,552,938

 

  

$

––

 

  

$

4,054,985

 

  

$

––

 

Cost of goods sold

 

 

7,101,076

 

 

 

952,028

 

 

 

3,685,366

 

 

 

952,028

 

Gross profit

 

 

451,862

 

 

 

(952,028

)

 

 

369,619

 

 

 

(952,028

)

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

399,148

 

 

 

828,458

 

 

 

157,574

 

 

 

316,402

 

Selling, general and administrative expenses

 

 

4,680,229

 

 

 

7,540,720

 

 

 

1,256,482

 

 

 

1,921,372

 

Loss on forward purchase commitments

 

 

––

 

 

 

532,500

 

 

 

––

 

 

 

532,500

 

Impairment of long lived assets

 

 

2,086,350

 

 

 

––

 

 

 

2,086,350

 

 

 

––

 

Operating loss

 

 

(6,713,865

)

 

 

(9,853,706

)

 

 

(3,130,787

)

 

 

(3,722,302

)

  

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income / (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

19,526

 

 

 

32,544

 

 

 

6,565

 

 

 

58

 

 Interest expense

 

 

(2,137,212

)

 

 

(253,020

)

 

 

(692,714

)

 

 

––

 

 Other income, net of expenses

 

 

60,535

 

 

 

113,321

 

 

 

32,258

 

 

 

71,160

 

 Share agreement cancellation payment

 

 

––

 

 

 

(900,000

)

 

 

––

 

 

 

––

 

 Registration rights payment

 

 

––

 

 

 

(2,274,402

)

 

 

––

 

 

 

––

 

  

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before income taxes

 

 

(8,771,016

)

 

 

(13,135,263

)

 

 

(3,784,678

)

 

 

(3,651,084

)

 Income taxes

 

 

(1,662

)

 

 

(21,560

)

 

 

––

 

 

 

––

 

  

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss 

 

 

(8,772,678

)

 

 

(13,156,823

)

 

 

(3,784,678

)

 

 

(3,651,084

)

 Less: Net loss attributable to the noncontrolling interest

 

 

(293,891

)

 

 

––

 

 

 

(117,637

)

 

 

––

 

Net loss attributable to AE Biofuels, Inc.

 

$

(8,478,787

)

 

$

(13,156,823

)

 

$

(3,667,041

)

 

$

(3,651,084

)

  

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive loss, net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Foreign currency translation adjustment

 

 

(284,684

)

 

 

2,537,516

 

 

 

(180,250

)

 

 

1,090,458

 

Comprehensive loss, net of tax

 

 

(9,057,362

)

 

 

(10,619,307

)

 

 

(3,964,928

)

 

 

(2,560,626

)

 Comprehensive loss attributable to the noncontrolling interest

 

 

––

 

 

 

––

 

 

 

––

 

 

 

––

 

Comprehensive loss attributable to AE Biofuels, Inc.

 

$

(9,057,362

)

 

$

(10,619,307

)

 

$

(3,964,928

)

 

$

(2,560,626

)

  

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per common share attributable to AE Biofuels, Inc.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Basic and dilutive

 

$

(0.10

)

 

$

(0.16

)

 

$

(0.04

)

 

$

(0.04

)

Weighted average shares outstanding

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Basic and dilutive

 

 

86,087,653

 

 

 

84,459,343

 

 

 

86,171,532

 

 

 

84,935,737

 



The accompanying notes are an integral part of the financial statements

2



AE BIOFUELS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

 

For the nine months ended

 

 

 

 

September 30,
2009

 

 

September 30,
2008

 

Operating activities:

  

     

                     

 

 

                        

 

Net loss

  

 

$

(8,772,678

)

   

$

(13,156,823

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

  Stock based compensation

 

 

605,909

 

 

 

1,776,882

 

  Expired land options

 

 

40,000

 

 

 

124,536

 

  Amortization and depreciation

 

 

529,263

 

 

 

168,284

 

  Inventory provision

 

 

336,114

 

 

 

952,028

 

  Amortization of debt discount

 

 

495,938

 

 

 

532,500

 

  Accrued interest expense

 

 

1,027,095

 

 

 

495,942

 

  Registration rights obligation

 

 

––

 

 

 

2,274,402

 

  Impairment of long lived assets

 

 

2,086,350

 

 

 

––

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

  Accounts receivable

 

 

326

 

 

 

9,490,481

 

  Inventory

 

 

(92,870

)

 

 

(2,280,540

)

  Prepaid expenses

 

 

88,698

 

 

 

(114,465

)

  Other current assets and other assets

 

 

664,666

 

 

 

(1,778,139

)

  Accounts payable

 

 

736,711

 

 

 

(8,637,365

)

  Other liabilities

 

 

324,254

 

 

 

2,882,172

 

  Income taxes payable

 

 

––

 

 

 

(29,775

)

Net cash used in operating activities

 

 

(1,930,224

)

 

 

(7,299,880

)

  

  

 

 

 

 

 

 

 

 

Investing activities:

  

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

 

(78,978

)

 

 

(5,918,939

)

Sales of time deposits

 

 

––

 

 

 

2,568,216

 

Cash payments to settle forward contracts

 

 

––

 

 

 

(198,213

)

Cash restricted by letter of credit

 

 

––

 

 

 

500,000

 

Net cash used in investing activities

 

 

(78,978

)

 

 

(3,048,936

)

  

  

 

 

 

 

 

 

 

 

Financing activities:

  

 

 

 

 

 

 

 

 

Proceeds from borrowings under related party credit facility

 

 

1,485,500

 

 

 

5,662,786

 

Payments of borrowings under related party credit facility

 

 

(169,630

)

 

 

––

 

Proceeds under working capital facility

 

 

2,255,536

 

 

 

––

 

Payments under working capital facility

 

 

(1,845,439

)

 

 

––

 

Proceeds from long term debt

 

 

––

 

 

 

4,469,547

 

Payments under long term debt facility

 

 

3,449

 

 

 

––

 

Proceeds from sale of preferred stock, net of offering costs

 

 

––

 

 

 

910

 

Net cash provided by financing activities

 

 

1,729,416

 

 

 

10,133,243

 

Effect of exchange rate changes on cash and cash equivalents

 

 

9,512

 

 

 

86,890

 

Net cash decrease for period

 

 

(270,274

)

 

 

(128,683

)

Cash and cash equivalents at beginning of period

 

 

377,905

 

 

 

720,402

 

Cash and cash equivalents at end of period

 

$

107,631

 

 

$

591,719

 

  

  

 

 

 

 

 

 

 

 

Supplemental disclosures of cash flow information, cash paid during the nine months for:  

 

 

 

 

 

Interest

  

 

 

281,480

 

 

 

––

 

Income taxes, net of refunds

 

 

––

 

 

 

––

 

Supplemental disclosures of cash flow information, non-cash transactions during the nine months for: 

 

 

 

 

 

Settlement of registration rights liability through issuance of stock

 

 

1,807,748

 

 

 

––

 




The accompanying notes are an integral part of the financial statements

3



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



1. Nature of Activities and Summary of Significant Accounting Policies.

Nature of Activities. These consolidated financial statements include the accounts of AE Biofuels, Inc., a Nevada corporation, and its wholly owned subsidiaries: (i) American Ethanol, Inc. (“American”), a Nevada corporation and its subsidiaries; Sutton Ethanol, LLC (“Sutton”), a Nebraska limited liability company, Illinois Valley Ethanol, LLC (“Illinois Valley”), an Illinois limited liability company; Danville Ethanol Inc, an Illinois corporation; AE Biofuels, Inc., (“AEB-DE”), a Delaware corporation and its subsidiary AE Renova, LLC (“AE Renova”), a Delaware limited liability company, (ii) Biofuels Marketing, a Delaware corporation; (iii) International Biodiesel, Inc., a Nevada corporation and its subsidiary AE International Biofuels, Ltd., a British Virgin Islands company, AE DAABON, Ltd., a British Virgin Islands company, International Biofuels, Ltd, a Mauritius corporation and its subsidiary Universal Biofuels Private Ltd, an India company; and (iv) AE Biofuels Americas, a Delaware corporation, and (v) AE Biofuels Technologies, Inc., a Delaware corporation and its subsidiary Energy Enzymes LLC, a Delaware limited liability company, collectively, (“AE Biofuels” or the “Company”).

The Company is an international biofuels company focused on the development, acquisition, construction and operation of next-generation fuel grade ethanol and biodiesel facilities, and the distribution, storage, and marketing of biofuels. The Company began selling fuel grade biodiesel from its production facility in Kakinada, India in November 2008 and began operating a cellulosic ethanol commercial demonstration facility in Butte, Montana in August 2008.

Development Stage Enterprise. The Company prepared its statements in accordance with the Development Stage Enterprise guidance as specified in FASB Accounting Standards Codification (“ASC”) ASC 915 (formerly SFAS No. 7 “Accounting and Reporting by Development Stage Enterprises”) until October 1, 2008, when planned principal operations commenced.

Basis of Presentation and Consolidation. The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The accompanying consolidated balance sheets as of September 30, 2009, the consolidated statements of operations for the three and nine months ended September 30, 2009 and 2008, and the consolidated statements of cash flows for the nine months ended September 30, 2009 and 2008 are unaudited. The consolidated balance sheet as of December 31, 2008 was derived from the 2008 audited consolidated financial statements and notes thereto. The consolidated financial statements in this report should be read in conjunction with the 2008 audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K and 10-K/A for the year ended December 31, 2008.

The accompanying unaudited interim consolidated financial statements as of September 30, 2009 and 2008 and for the three and nine months ended September 30, 2009 and 2008 have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations.

In the opinion of management, the unaudited interim consolidated financial statements for the three and nine months ended September 30, 2009 and 2008 have been prepared on the same basis as the audited consolidated statements as of December 31, 2008 and reflect all adjustments, consisting primarily of normal recurring adjustments, necessary for the fair presentation of its statement of financial position, results of operations and cash flows. The results of operations for the three and nine months ended September 30, 2009 are not necessarily indicative of the operating results for any subsequent quarter, for the full fiscal year or any future periods.

Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. Significant estimates, assumptions and judgments made by management include the determination of impairment of long-lived assets, the valuation of equity instruments such as options and warrants, the recognition and measurement of current taxes payable and deferred tax assets or liabilities, and the accrual for the payments under the Company's registration rights agreement with certain of its shareholders and management’s judgment about contingent liabilities. Management believes that the estimates and judgments upon which they rely



4



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



are reasonable based upon information available to them at the time that these estimates and judgments are made. To the extent there are material differences between these estimates and actual results, the Company’s consolidated financial statements will be affected.

Reclassifications. Certain prior year amounts were reclassified to conform to current year presentation. These reclassifications had no impact on previously reported net loss or accumulated deficit.

Revenue Recognition. The Company recognizes revenue when products are delivered, the price is fixed or determinable and collection is reasonably assured. This typically occurs upon shipment as payments are generally made in advance and products are sold without the right of return.

Cost of Goods Sold. Cost of goods sold include those costs directly associated with the production of revenues, such as raw material purchases, factory overhead, and other direct production costs.

Research and Development. Research and development costs are expensed as incurred, unless they have alternative future uses to the Company.

General and Administrative. General and administrative expenses include those costs associated with the general operations of our business such as: compensation, rent, consultants, and travel related to executive, legal and financial functions.

Cash and Cash Equivalents. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company maintains cash balances at various financial institutions domestically and abroad. Domestic accounts are insured by the FDIC. The Company’s accounts at these institutions may exceed federally insured limits. The Company has not experienced any losses in such accounts.

Inventories. Inventories are stated at the lower of cost, using the first-in and first-out (FIFO) method, or market.

Property, Plant and Equipment. Property, plant and equipment are carried at cost less accumulated depreciation after assets are placed in service and are comprised primarily of land acquired for development of production facilities, and the biodiesel plant in India. The estimated useful life of this plant is 20 years. The estimated useful life for office equipment and computers is three years and the useful life of machinery and equipment is seven years. Depreciation is computed using the straight line method over the useful life of the assets.

Intangible Assets. Intangible assets are carried at initial fair value less accumulated amortization over the estimated useful life. Amortization is computed over the estimated useful lives of the underlying assets using a method that reflects their utilization pattern.

Income Taxes. The Company recognizes income taxes in accordance with ASC 740 (formerly SFAS No. 109, “Accounting for Income Taxes”), using an asset and liability approach. This approach requires the recognition of taxes payable or refundable for the current year and deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements or tax returns. The measurement of current and deferred taxes is based on provisions of enacted tax law.

ASC 740 provides for recognition of deferred tax assets if the realization of such assets is more likely than not to occur. Otherwise, a valuation allowance is established for the deferred tax assets which may not be realized. As of December 31, 2008, the Company recorded a full valuation allowance against its net deferred tax assets due to operating losses incurred since inception. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets were fully offset by a valuation allowance.

The Company is subject to income tax audits by the respective tax authorities in all of the jurisdictions in which it operates. The determination of tax liabilities in each of these jurisdictions requires the interpretation and application of complex and sometimes uncertain tax laws and regulations. The recognition and measurement of current taxes payable or refundable and deferred tax assets and liabilities requires that the Company make certain estimates and judgments. Changes to these estimates or a change in judgment may have a material impact on the Company’s tax provision in a future period.



5



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



Effective January 1, 2007, the Company adopted ASC Section 740-10-25 (formerly FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes - an interpretation on FASB Statement No. 109”) which requires a more-likely-than-not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. The Company records a liability for the difference between the benefit recognized and measured pursuant to ASC Section 740-10-25 and the tax position taken or expected to be taken on its tax return. To the extent that the Company’s assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. With the adoption of ASC Section 740-10-25, the Company also began reporting tax-related interest and penalties as a component of income tax expense.

Long-Lived Assets. The Company evaluates the recoverability of long-lived assets with finite lives in accordance with ASC Subtopic 360-10-35 (formerly SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets”) which requires recognition of impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable based on estimated undiscounted cash flows, the impairment loss would be measured as the difference between the carrying amount of the assets and its fair value based on the net present value of estimated future cash flows.

Basic and Diluted Net Loss per Share. Basic loss per share is computed by dividing loss attributable to common shareholders by the weighted average number of common shares outstanding for the period, net of shares subject to repurchase. Diluted net loss per share reflects the dilution of common stock equivalents such as options, convertible preferred stock and warrants to the extent the impact is dilutive. Basic loss per share includes the vested portion of restricted stock grants. Unvested restricted stock grants are included only in the fully diluted net loss per share calculation. As the Company incurred net losses for the three months ended September 30, 2009 and 2008, potentially dilutive securities have been excluded from the diluted net loss per share computations as their effect would be anti-dilutive.

The following table shows the weighted-average number of potentially dilutive shares excluded from the diluted net loss per share calculation for the three months ended September 30, 2009 and 2008:

 

 

 

For the nine  months ended

 

 

For the three  months ended

 

 

 

 

September 30,

2009

 

 

 

September 30,

2008

 

 

 

September 30,

2009

 

 

September 30,

2008

 

Series B preferred stock

 

 

3,340,979

 

 

 

6,185,756

 

 

 

3,330,725

 

 

5,880,104

 

Series B warrants

 

 

443,853

 

 

 

726,200

 

 

 

443,853

 

 

718,908

 

Common stock options and warrants

 

 

3,784,946

 

 

 

4,781,046

 

 

 

5,137,684

 

 

5,575,750

 

Unvested restricted stock

 

 

10,989

 

 

 

415,693

 

 

 

––

 

 

250,000

 

Total weighted average number of potentially dilutive shares
excluded from the diluted net loss per share calculation

 

 

7,580,767

 

 

 

12,108,695

 

 

 

8,912,262

 

 

12,424,762

 

Comprehensive Income. ASC 220 (formerly SFAS No. 130, "Reporting Comprehensive Income"), requires that an enterprise report, by major components and as a single total, the change in its net assets from non-owner sources. The Company’s other comprehensive income consists solely of cumulative foreign currency translation adjustments resulting from the translation of the financial statements of its India subsidiary. The investment in this subsidiary is considered indefinitely invested overseas and, as a result, deferred income taxes are not recorded related to the currency translation adjustments.

Foreign Currency Translation/Transactions. Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where that local currency is the functional currency, are translated into U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive income. Income and expense accounts are translated at average exchange rates during the year. Gains and losses from foreign currency transactions are recorded in other income (loss), net. The functional currency is the local currency for all non-U.S. subsidiaries.

Restricted Stock. The Company has granted restricted stock awards, restricted by a service condition, with vesting periods of up to three years. Restricted stock awards are valued using the fair market value of the Company’s common stock as of the grant date. The Company recognizes compensation expense on a straight line basis over the requisite service period of the award. The remaining unvested shares are subject to forfeitures and restrictions on sale, or transfer, up until the vesting date.



6



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



Stock-Based Compensation Expense. Effective January 1, 2006, we adopted the fair value recognition provisions of ASC 715-20-50 (formerly SFAS No. 123 (Revised 2004), “Share-Based Payment”), requiring us to recognize expense related to the fair value of our stock-based compensation awards adjusted to reflect only those shares that are expected to vest. Our implementation of ASC Section 715-20-50 used the modified-prospective-transition method.

We made the following estimates and assumptions in determining fair value of stock options as prescribed by ASC Section 715-20-50:

·

Valuation and Amortization Method — The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing formula and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.

·

Expected Term — The expected term represents the weighted-average period that our stock-based awards are expected to be outstanding. We applied the “Simplified Method” as defined in the Securities and Exchange Commission’s Staff Accounting Bulletin No. 107 and 110.

·

Expected Volatility — The Company’s expected volatilities are based on the historical volatility of comparable public companies’ stock for a period consistent with our expected term.

·

Expected Dividend — The Black-Scholes-Merton valuation model calls for a single expected dividend yield as an input. The Company currently pays no dividends and does not expect to pay dividends in the foreseeable future.

·

Risk-Free Interest Rate — The Company bases the risk-free interest rate on the implied yield currently available on United States Treasury zero-coupon issues with an equivalent remaining term.

Commitments and Contingencies. The Company records and/or discloses commitments and contingencies in accordance with ASC 450, “Contingencies”, (ASC 450). ASC 450 applies to an existing condition, situation, or set of circumstances involving uncertainty as to possible loss that will ultimately be resolved when one or more future events occur or fail to occur. As of September 30, 2009, the Company is not aware of any material commitments or contingencies other than those disclosed in Note 16. Contingent Liabilities.

Recent Accounting Pronouncements.

The Company adopted the provisions of ASC 820-10, Fair Value Measurements and Disclosures (formerly SFAS No. 157, Fair Value Measurements), with respect to non-financial assets and liabilities effective January 1, 2009. This pronouncement defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. The adoption of ASC 820-10 did not have an impact on the Company’s consolidated financial statements.

The Company adopted ASC 805 (formerly SFAS No. 141(R), “Business Combinations”) for business combinations. This topic changes the accounting for acquisition transaction costs by requiring them to be expensed in the period incurred, and also changes the accounting for contingent consideration, acquired contingencies and restructuring costs related to an acquisition. The Company also adopted ASC 810-10-65, Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51 (formerly SFAS No. 160, “Non-controlling Interests in Consolidated Financial Statements-an amendment of ARB No. 51”). This statement changes the accounting and reporting for minority interests, which are re-characterized as non-controlling interests, classified as a component of equity and accounted for at fair value. ASC 805 and ASC 810-10-65 are effective for the Company’s 2009 financial statements. Early adoption is prohibited. The effect the adoption of ASC 805 has had and will have on the Company’s financial statements will depend on the nature and size of acquisitions we complete after adoption. We adopted ASC 810-10-65-1 as of January 1, 2009. As a result, we reclassified the 49% non-controlling interest in our subsidiary Energy Enzymes, Inc., prospectively. Had we continued to apply the prior method of accounting for non-controlling interests, losses incurred by this entity would have been fully attributed to us.



7



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



The Company adopted ASC 825-10 (formerly the Financial Accounting Standards Board (FASB) issued Staff Position SFAS 107-1 and Accounting Principles Board (APB) Opinion No. 28-1, “Interim Disclosures about Fair Value of Financial Instruments”). ASC 825-10 amends FASB Statement No. 107, “Disclosures about Fair Values of Financial Instruments,” to require disclosures about fair value of financial instruments in interim financial statements as well as in annual financial statements. APB 28-1 amends APB Opinion No. 28, “Interim Financial Reporting,” to require those disclosures in all interim financial statements. ASC 825-10 is effective for interim periods ending after June 15, 2009. Adoption of this statement did not have a material effect on the Company’s financial statements. See Note 17 Fair Value Measurement.

The Company adopted ASC 320-10 (formerly Staff Position SFAS 115-2 and SFAS 124-2, “Recognition and Presentation of Other-Than-Temporary Impairments”. ASC 320 provides guidance in determining whether impairments in debt securities are other than temporary, and modifies the presentation and disclosures surrounding such instruments. ASC 320 is effective for interim periods ending after June 15, 2009. Adoption of this statement did not have a material effect on the Company’s financial statements.

In June 2009, the FASB issued ASC 105 (formerly SFAS No. 168, "The FASB Accounting Standards Codification (TM) ("Codification") and the Hierarchy of Generally Accepted Accounting Principles - a replacement of FASB Statement No. 162"). ASC 105 establishes the Codification as the single official source of authoritative United States accounting and reporting standards for all non-governmental entities (other than guidance issued by the SEC). The Codification changes the referencing and organization on financial standards and is effective for interim and annual periods ending on or after September 15, 2009. ASC 105 is not intended to change the existing accounting guidance and its adoption did not have an impact on our financial statements.

In October, the FASB issued EITF Issue no. 2009-13, Revenue Recognition (Topic 605), Multiple Deliverable Revenue Arrangements, which applies to multiple-deliverable revenue arrangements that are currently within the scope of FASB ASC 605-25 (previously included in EITF Issue no. 00-21, Revenue Arrangements with Multiple Deliverables). The EITF will be effective on a prospective basis for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. The Company has not fully assessed the impact of this guidance, but at this time believes it will not have an impact on our financial statements.

In August 2009, the FASB issued Accounting Standard Update (“ASU”) ASU 2009-5, “Fair Value Measurements and Disclosures (Topic 820) – Measuring Liabilities at Fair Value” (“ASU 2009-5”). This update provides clarification of the fair value measurement of financial liabilities when a quoted price in an active market for an identical liability (Level 1 input of the valuation hierarchy) is not available. ASU 2009-5 is effective in the fourth quarter of 2009. The Company does not anticipate this update will have a material impact on its financial statements or disclosures.

2. Ability to Continue as a Going Concern.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has experienced losses and negative cash flow since inception and currently has an accumulated deficit and a negative stockholders’ equity balance. These factors raise substantial doubt about its ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent on several factors, including the ability to raise a significant amount of capital for operating expenses, capital expenses , current liabilities and debt service.

The Company has produced minimal gross profit, has less than one month of operating cash, has incurred losses from inception through September 30, 2009 and has negative working capital (current assets less current liabilities) of $19,928,277. The Company has raised approximately $31.8 million to date through the sale of preferred stock and approximately $12.6 million through debt facilities. An additional $2 million of cash has been generated through the sale of its subsidiary, Wahoo Ethanol, LLC, with an additional $8 million through the dissolution of the Sutton Ethanol Joint venture. The Company will have to raise significantly more capital and secure a significant amount of debt to complete its business plan and continue as a going concern. The Company has one biodiesel production facility in operation that began selling biodiesel into the domestic Indian market in November 2008. Although the biodiesel plant provides some cash flow to the Company it will likely be insufficient to allow for the completion of our business plan in fiscal 2009.



8



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



Management believes that it will be able to raise additional capital through equity offerings and debt financings. Should the Company not be able to raise enough capital it may be forced to sell all or a portion of its existing biodiesel facility or other assets at a discount to market value and may incur additional impairment related to these assets to generate cash to continue the Company’s business plan or possibly discontinue operations. Until such additional capital is raised, the Company is dependent on financing from a related party. The Company has also arranged extended terms with our trade creditors. The Company’s goal is to raise additional funds needed to construct and operate next generation ethanol and biodiesel facilities through stock offerings and debt financings. There can be no assurance that additional financing will be available on terms satisfactory to the Company. The accompanying financial statements do not include any adjustments that may result should the Company be unable to continue as a going concern.

3. Inventory.

Inventory consists of the following:

 

 

September 30,
2009

 

 

December 31,

2008

 

Raw materials

 

$

560,319

 

 

$

674,069

 

Work-in-progress

 

 

61,518

 

 

 

53,251

 

Finished goods

 

 

196,699

 

 

 

322,263

 

Total inventory

 

$

818,536

 

 

$

1,049,583

 

For the three and nine months ended September 30, 2009 the Company expensed $101,549 and $335,722, respectively, in connection with the write-down of inventory to reflect market value below cost. During the three and nine months ended September 30, 2008 the Company expensed $952,028 in connection with write down of inventory to reflect market value below cost.

4. Property, Plant and Equipment.

Property, plant and equipment consist of the following:

 

 

September 30,

2009

 

December 31,

2008

 

Land

 

$

3,338,445

 

$

3,656,676

 

Buildings

 

 

11,825,495

 

 

12,445,883

 

Furniture and fixtures

 

 

82,183

 

 

73,983

 

Machinery and equipment

 

 

546,012

 

 

618,487

 

Construction in progress

 

 

3,174,418

 

 

4,648,149

 

Total gross property, plant & equipment

 

 

18,966,553

 

 

21,443,178

 

Less: accumulated depreciation

 

 

(726,774

)

 

(206,574

)

 Total net property, plant and equipment

 

$

18,239,779

 

$

21,236,604

 

For the three and nine months ended September 30, 2009 the Company recorded $182,548 and $542,263, respectively, in depreciation expense. During the three and nine months ended September 30, 2008 the Company recorded $9,351 and $18,070, respectively in depreciation expense.

Components of construction in progress include $2,886,825 related to our India biodiesel pretreatment and glycerin facility and $975,594 related to the development of our Sutton property (held for future development of a next generation cellulosic ethanol facility). The estimated cost to complete construction of the pretreatment and glycerin facility is $1,000,000. Commitments for approximately $22,328 under construction contracts, purchase orders and other short term contracts were outstanding at September 30, 2009.

An impairment charge of $2,086,350 was taken during the three months ended September 30, 2009 related to the Sutton and Danville land holdings within our North American segment. The Company believes that in light of the default on the senior debt facility and the collateralization of these properties under the term of the loan agreement, as well as the challenging global economic conditions, the Company is required to reevaluate the potential future development of these properties. The impairment charge is the difference between the estimated fair value determined by management after considering available information including appraisals of the respective properties (based on Level 2 inputs) and the current carrying value.



9



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



5. Other Current Assets and Other Assets.

Other current assets and other assets consists of foreign input tax credits, restricted cash, payments for land options for possible future ethanol plants, supplier deposits and other prepayments.

 

 

September 30,
2009

 

 

December 31,

2008

 

Current

 

 

 

 

 

 

Short term deposits

 

$

 56,087

 

 

$

235,119

 

Foreign input and custom duty credits

 

 

402,081

 

 

 

112,925

 

Land options

 

 

––

 

 

 

40,000

 

Other

 

 

76,390

 

 

 

50,659

 

Total other current assets 

 

$

534,558

 

 

$

438,703

 

Long Term

 

 

 

 

 

 

 

 

Restricted cash

 

 

––

 

 

 

267,600

 

Deposits

 

 

38,600

 

 

 

22,390

 

Total other assets 

 

$

38,600

 

 

$

289,990

 

The Company acquired options to purchase land in various locations in Nebraska and Illinois. These options gave the Company the right to buy specific property for a set price per acre and typically ended in one to two years. As of December 31, 2008, the Company had one option to purchase land in Illinois for $934,000. This option expired in May 2009, and was expensed during the three months ended March 31, 2009 upon management’s determination not to renew. For the three and nine months ended September 30, 2009, the Company expensed options that ended or were released in the amount of $40,000. For the three and nine months ended September 30, 2008, the Company expensed options that ended or were released in the amount of $0 and $124,536, respectively.

Foreign input and custom duty credits represent payment of tax to governmental agencies where the Company expects to receive reimbursement upon the filing of returns or the application of these funds to reduce the payment of future taxes.

6. Intangible Assets.

Intangible assets consist of purchased customer lists (acquired in 2007 in connection with the acquisition of Biofuels Marketing, Inc. discussed in Note 12 below), which have been amortized over an estimated useful life of 18 months. The intangible assets have a cost basis of $300,000 and a net carrying amount of $0 and $33,334 at September 30, 2009 and December 31, 2008, respectively. For the three and nine months ended September 30, 2009, the Company recorded amortization of $0 and $33,334, respectively. For the three and nine months ended September 30, 2008, the Company recorded amortization of $50,000 and $150,000, respectively.

7. Debt.

Debt consists of the following:

 

 

September 30,

2009

 

 

December 31,

2008

 

Revolving line of credit (related party)

 

$

––

 

 

$

2,044,691

 

Secured term loan, net of unamortized discount

 

 

––

 

 

 

3,991,013

 

Less: current portion

 

 

––

 

 

 

(816,738

)

Total long term debt

 

 

––

 

 

 

5,218,966

 

Senior secured note, including accrued interest of $818,369

 

 

5,818,369

 

 

 

4,504,062

 

Unsecured working capital loan, including accrued interest of $5,485

 

 

423,896

 

 

 

––

 

Current portion of long term debt

 

 

4,084,013

 

 

 

816,738

 

Current portion of long term debt (related party)

 

 

3,650,819

 

 

 

––

 

Total current debt

 

 

13,977,097

 

 

 

5,320,800

 

Total debt

 

$

13,977,097

 

 

$

10,539,766

 



10



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)






Senior secured note. On May 16, 2008, Third Eye Capital ABL Opportunities Fund (“Purchaser”) purchased a 10% senior secured note in the amount of $5 million along with 5 year warrants exercisable for 250,000 shares of common stock at an exercise price of $3.00 per share. The note is secured by first-lien deeds of trust on real property located in Nebraska and Illinois, by a first priority security interest in equipment located in Montana, and a guarantee of $1 million by McAfee Capital LLC (owned by Eric McAfee and his wife). Interest on the note accrues on the unpaid principal balance and is payable on the first business day of each quarter beginning on July 1, 2008. Prior to the note maturing on May 15, 2009, the Company entered into an amendment and limited waiver (the “Amendment”) with Third Eye Capital Corporation (“Agent”) on behalf of itself and the Purchaser dated March 31, 2009. The Amendment did not become effective as we were unable to meet the conditions of effectiveness set forth in the Amendment. Accordingly, the interest rate under this facility has been accrued at the default interest rate, which is 18%, during the period of default. The Company has no cross default provisions in this or any other debt agreement. As a result, our inability to execute the conditions of effectiveness of the Amendment will have no adverse impact on our other debt obligations. Nevertheless, the failure to execute the effectiveness of the Amendment may have an adverse impact on our ability to obtain additional borrowings.

On August 11, 2009, the Company received a notice of default under the Note and Warrant Purchase Agreement asserting that the Company failed to maintain its current ratio and stock market capitalization covenants and as a result Events of Default have occurred and are continuing. The notice of default demands repayment of the entire outstanding indebtedness of $5 million together with all accrued interest thereon and any applicable fees and expenses. We are currently in discussions with the Purchaser with regards to an amendment to the Note and Warrant Purchase Agreement for the modification of terms.

Secured term loan. On July 17, 2008, Universal Biofuels Private Limited (“UBPL”), a wholly-owned subsidiary, entered into a six year secured term loan with the State Bank of India with an overall limit in the amount of approximately $6 million. The term loan matures in March 2014 and is secured by UBPL’s assets, consisting of the biodiesel plant and land in Kakinada. In July 2008 we drew approximately $4.6 million against the secured term loan. The loan principal amount is repayable in 20 quarterly installments of approximately $250,000, using exchange rates on September 30, 2009, with the first installment due in June 2009 and the last installment payment due in March 2014. The interest rate under this facility is subject to adjustment every two years, based on 0.25% above the Reserve Bank of India advance rate and is currently 12.00%.

The principal payment scheduled for June 2009 and September 2009 were not made and in the event of default of payment of any installment of principal payments, the term loan provides for liquidating damages at a rate of 2% per annum for the period of default.

On October 7, 2009, UBPL received a demand notice from the State Bank of India. The notice informs UBPL that an event of default has occurred for failure to make an installment payment on the loan due in June, 2009 and demands repayment of the entire outstanding indebtedness of 19.60 crores (approximately $4 million) together with all accrued interest thereon and any applicable fees and expenses by October 10, 2009. Upon the occurrence and during the continuance of an Event of Default, interest accrues at the default interest rate of 2% above the State Bank of India Advance Rate pursuant to the Agreement of Loan for Overall Limit. The default period began on July 1, 2009 when the principal payment was deemed past due; therefore, we have accrued for the liquidating damages for the period of default in July and August. As of September 30, 2009, UBPL was in default on one month of interest as well as the principal payment due July 1, 2009. Additional provisions of default include the bank having the unqualified right to disclose or publish our company name and our directors names as defaulter in any medium or media. At the bank’s option, it may also demand payment of the balance of the loan since the principal payments are in default in July 2009 so we have classified the entire loan amount as current. We are currently in discussions with the bank with regards to an amendment to the Agreement of Loan for Overall Limit for the modification of terms.

Revolving line of credit – related party. On November 16, 2006, the Company entered into a short-term loan agreement with Mr. Laird Cagan, a former member of the Company’s board of directors and a significant stockholder. In 2008 and 2009 this short-term loan agreement was amended to convert the facility into an unsecured revolving line of credit with a credit limit of $3,500,000. In addition, the maturity date of the credit facility was extended to July 1, 2011.



11



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



On August 17, 2009, International Biodiesel, Inc., a wholly owned subsidiary of AE Biofuels, Inc., entered into a Revolving Line of Credit Agreement with Mr. Cagan, (the “Lender”), for $5,000,000. The $5,000,000 Revolving Line of Credit is secured by accounts, investments, intellectual property, securities and other collateral of AE Biofuels, Inc. excluding the collateral securing the Company’s obligations under the Note and Warrant Purchase Agreement with Third Eye Capital Corporation and Third Eye Capital ABL Opportunities Fund. The $5,000,000 Revolving Line of Credit bears interest at the rate of 10% per annum and matures on July 1, 2011, at which time the outstanding advances under the Revolving Line of Credit together with any accrued interest and other unpaid charges or fees will become due. Upon certain events, one of which is the default on any other debt facility, the Lender may declare a default upon 10 days prior written notice. Upon an event of default, the Lender may accelerate the outstanding indebtedness together with all accrued interest thereon and demand immediate repayment. The Company used the new Revolving Line of Credit Agreement to pay down the unsecured revolving line of credit facility with a limit of $3,500,000 in August 2009.

At September 30, 2009, a total of $3,650,819, including accrued interest, was outstanding under the $5,000,000 Revolving Line of Credit, dated August 17, 2009. All outstanding principal and accrued interest is due and payable on July1, 2011.

Operating Agreement. In November 2008, the Company entered into an operating agreement with Secunderabad Oils Limited (“Secunderabad”). Under this agreement Secunderabad agreed to provide the Company with working capital, on an as needed basis, to fund the purchase of feedstock and other raw materials for our Kakinada biodiesel facility. Working capital advances bear interest at the actual bank borrowing rate of Secunderabad, currently at 15%. During the three and nine months ended September 30, 2009, the Company paid Secunderabad approximately $52,793 and $60,239, respectively, in interest for working capital funding. At September 30, 2009 and December 31, 2008 the Company had $423,896 and $0 outstanding under this agreement, respectively, and included as current short term borrowings on the balance sheet.

8. Operating Leases.

The Company, through its subsidiaries, has non-cancelable operating leases for office space in Cupertino and India as well as the property housing our cellulosic demonstration facility in Butte, Montana. These leases expire at various dates through May 31, 2012. The Company records rent expense on a straight line basis.

Future minimum operating lease payments as of September 30, 2009, are:

 

 

Rental

Payments

 

2009

 

$

71,134

 

2010

 

 

263,846

 

2011

 

 

260,206

 

2012

 

 

97,577

 

Total

 

$

692,763

 


For the three and nine months ended September 30, 2009, the Company recorded $61,159 and $194,454, respectively, in rent expense.

In July, 2009, the Company entered into a sublease agreement with Solargen Energy, Inc. for approximately 3,000 square feet of leased space. For the three months ended September 30, 2009, the Company invoiced, collected and offset as rent expense $21,418 under this agreement. The future minimum lease payments above exclude collections of rent under this sublease agreement. See Note 14 Related Party Transactions.

9. Stockholders’ Deficit.

The Company is authorized to issue up to 400,000,000 shares of common stock, $0.001 par value and 65,000,000 shares of preferred stock, $0.001 par value, of which 7,235,565 shares were designated Series B preferred stock, 3,330,725 shares of which were outstanding as of September 30, 2009.



12



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



Convertible Preferred Stock

Significant terms of the Series B preferred stock are as follows:

Voting. Holders of our Series B preferred stock are entitled to the number of votes equal to the number of shares of Common Stock into which the shares of Series B preferred stock held by such holder could be converted as of the record date. Cumulative voting with respect to the election of directors is not allowed. Currently each share of Series B preferred stock is entitled to one vote per share of Series B preferred stock. In addition, without obtaining the approval of the holders of a majority of the outstanding preferred stock, the Company cannot:

·

Increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series B preferred stock;

·

Effect an exchange, reclassification, or cancellation of all or a part of the Series B preferred stock, including a reverse stock split, but excluding a stock split;

·

Effect an exchange, or create a right of exchange, of all or part of the shares of another class of shares into shares of Series B preferred stock; or

·

Alter or change the rights, preferences or privileges of the shares of Series B preferred stock so as to affect adversely the shares of such series.

Dividends. Holders of all of our shares of Series B preferred stock are entitled to receive non-cumulative dividends payable in preference and before any declaration or payment of any dividend on common stock as may from time to time be declared by the board of directors out of funds legally available for that purpose at the rate of 5% of the original purchase price of such shares of preferred stock. No dividends may be made with respect to our common stock until all declared dividends on the preferred stock have been paid or set aside for payment to the preferred stock holders. To date, no dividends have been declared.

Liquidation Preference. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of the Series B preferred stock are entitled to receive, prior and in preference to any payment to the holders of the common stock, $3.00 per share plus all declared but unpaid dividends (if any) on the Series B preferred stock. If the Company’s assets legally available for distribution to the holders of the Series B preferred stock are insufficient to permit the payment to such holders of their full liquidation preference, then the Company’s entire assets legally available for distribution are distributed to the holders of the Series B preferred stock in proportion to their liquidation preferences. After the payment to the holders of the Series B preferred stock of their liquidation preference, the Company’s remaining assets legally available for distribution are distributed to the holders of the common stock in proportion to the number of shares of common stock held by them. A liquidation, dissolution or winding up includes (a) the acquisition of the Company by another entity by means of any transaction or series of related transactions to which the Company is party (including, without limitation, any stock acquisition, reorganization, merger or consolidation but excluding any sale of stock for capital raising purposes) that results in the voting securities of the Company outstanding immediately prior thereto failing to represent immediately after such transaction or series of transactions (either by remaining outstanding or by being converted into voting securities of the surviving entity or the entity that controls such surviving entity) a majority of the total voting power represented by the outstanding voting securities of the Company, such surviving entity or the entity that controls such surviving entity, or (b) a sale, lease or other conveyance of all or substantially all of the assets of the Company.

Conversion. Holders of Series B preferred stock have the right, at their option at any time, to convert any shares into common stock. Each share of preferred stock will convert into one share of common stock, at the current conversion rate. The conversion ratio is subject to adjustment from time to time in the event of certain dilutive issuances and events, such as stock splits, stock dividends, stock combinations, reclassifications, exchanges and the like. In addition, at such time as the Registration Statement covering the resale of the shares of common stock is issuable, then all outstanding Series B preferred stock shall be automatically converted into common stock at the then effective conversion rate. For the three months ended September 30, 2009, no shares of Series B preferred stock were converted into shares of common stock.



13



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



Registration Rights Agreement liquidated damages for certain common and Series B preferred shareholders. Certain holders of shares of our common stock and holders of shares of our Series B preferred stock were entitled to have their shares of common stock (including common stock issuable upon conversion of Series B preferred stock) registered under the Securities Act within but no later than 30 days after December 7, 2007, pursuant to the terms and subject to the conditions set forth in a Registration Rights Agreement entered into among the Company and such holders. Registration of these shares under the Securities Act would result in these shares becoming freely tradable without restriction under the Securities Act.

In February 2009, in full settlement of the $1,807,748 registration right liability, the Company issued a total of 406,656 shares of its common stock to eligible shareholders resulting in a reduction of the liability and a corresponding increase in additional paid in capital and common stock.

Mandatorily Redeemable Series B preferred stock. In connection with the election of dissenters’ rights by the Cordillera Fund, L.P., at December 31, 2008 the Company reclassified 583,334 shares of Series B preferred stock with an original purchase price of $1,750,002 out of shareholders’ equity to a liability called “mandatorily redeemable Series B preferred stock” and accordingly reduced stockholders equity by the same amount to reflect the Company’s estimate of its obligations with respect to this matter. See Note 16 – Contingent Liabilities.

Common Stock

On October 6, 2008, the Company and TIC cancelled their Strategic Alliance Agreement and TIC agreed to return 4,000,000 shares of the Company’s common stock for a total payment of $500,000 by the Company of which $234,419 was paid to TIC upon the parties’ entry into the agreement and $265,581 was payable on or before December 30, 2008. Upon cancellation of the agreement, TIC returned 1,880,000 shares and will return the remaining 2,120,000 shares upon the receipt of the final payment. In the event the final payment is not received on or before December 30, 2008, interest shall begin to accrue at the annual rate of 18% until paid in full. At September 30, 2009, the Company had not made the payment required under the agreement. As of September 30, 2009, the Company accrued interest of $37,534 related to this obligation.

10. Private Placement of Preferred Stock and Warrants.

In connection with the sale of our Series A and B preferred stock, we issued to our placement agent warrants to purchase a number of shares of our common stock representing up to 8% of the shares of Series A and Series B preferred stock sold. The warrants are exercisable for a period of seven years from the date of issuance, have a net exercise provision and are transferable. Further, subject to certain conditions, the Company has indemnified the placement agents and affiliated broker-dealers against certain civil liabilities, including liabilities under the Securities Act.

A summary of warrant activity for placement warrants for 2009 is as follows:

 

Number of

Warrants

 

Weighted

Average

Exercise

Price

 

Warrants

Exercisable

 

Remaining

Term

(years)

 

Outstanding, December 31, 2008

666,587

 

$

3.00

 

666,587

 

3.45

 

Granted

––

 

 

––

 

 

 

 

 

Exercised

––

 

 

––

 

 

 

 

 

Outstanding, September 30, 2009

666,587

 

 

3.00

 

666,587

 

2.70

 

The warrants are considered equity instruments. Since they were issued as a cost of the issuance of the Series A and B preferred stock, the fair value of these warrants has effectively been netted against the preferred stock sale proceeds.

One former member of the Company’s board of directors and a significant shareholder of the Company was a registered representative of the placement agent. He received a portion of the compensation paid to the placement agent and received 976,721 of the warrants issued from the Series A and B financing. During 2008, he exercised warrants for 801,721 shares of our common stock and transferred 175,000 warrants to another individual.



14



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



Warrants

In May 2008, we issued 250,000 common stock warrants to Third Eye Capital in connection with the sale of a 10% senior secured note. These warrants are immediately exercisable at $3.00 per share.

In February 2007, we issued 5,000 warrants to a consultant as compensation for services rendered. These warrants are immediately exercisable at $3.00 per share.

11. Stock-Based Compensation.

Common Stock Reserved for Issuance

We authorized the issuance of 4,882,410 shares under the 2007 Stock Plan for stock option awards, which includes both incentive and non-statutory stock options. Options granted under the Plan generally expire five years from the date of grant and are exercisable at any time after the date of the grant, subject to vesting. Shares issued upon exercise before vesting are subject to a right of repurchase, which lapses according to the vesting schedule of the original option.

The following is a summary of options granted under the 2007 Stock Plan:

 

 

 

 

 

Options Outstanding

 

 

 

Shares

Available For

Grant

 

 

Number of

Shares

 

 

Weighted

Average

Exercise Price

 

Balance as of December 31, 2008

 

 

1,490,500

 

 

 

2,509,500

 

 

$

3.24

 

Authorized

 

 

882,410

 

 

 

––

 

 

 

 

 

Granted

 

 

(2,884,000

)

 

 

2,884,000

 

 

$

0.16

 

Exercised

 

 

––

 

 

 

––

 

 

 

––

 

Forfeited

 

 

691,625

 

 

 

(691,625

)

 

 

3.16

 

Balance as of September 30, 2009

 

 

180,535

 

 

 

4,701,875

 

 

$

1.36

 

At September 30, 2009, the weighted average remaining contractual term is 4.50 years. The aggregate intrinsic value of the shares outstanding at September 30, 2009 is $0. The aggregate intrinsic value represents the total pretax intrinsic value, based on the excess of the Company’s closing stock price at September 30, 2009 of $0.26, over the options holders’ strike price, which would have been received by the option holders had all option holders exercised their options as of that date. The weighted average grant date fair value of these awards at September 30, 2009 is $0.64. Options vested and exercisable at September 30, 2009 were 2,954,749 with a weighted average exercise price of $1.58.

Included in the table above are 727,000 options issued to consultants in November 2007, September 2008, May 2009 and August 2009. These options had an exercise price of $3.00, $3.70, $0.16 and $0.15, respectively, and generally vest over 3 years. At September 30, 2009 the weighted average remaining contractual term was 3.60 years. The Company recorded an expense for the three and nine months ended September 30, 2009 in the amount of $16,004 and $19,274, respectively, which reflects periodic fair value re-measurement of outstanding consultant options under ASC 505-50-30 (formerly Emerging Issues Task Force, or EITF, No. 96-18, “Accounting for Equity Instruments that are issued to Other Employees for Acquiring, or in Conjunction with Selling, Goods or Services,” ). The valuation using the Black-Scholes-Merton model is based upon the current market value of our common stock and other current assumptions, including the expected term (contractual term for consultant options). The Company records the expense related to consultant options using the accelerated expense pattern prescribed in ASC 505-50-30.

Valuation and Expense Information under ASC Section 715-20-50 (formerly SFAS 123(R))

The Company incurred non-cash stock compensation expense of $153,635 and $630,909 for the three and nine months ended September 30, 2009, respectively, for options granted to our general and administrative employees and consultants. Of the non-cash stock compensation expense for the three and nine months ended September 30, 2009, $25,000 and $100,000, respectively, was attributable to stock granted to an officer pursuant to the acquisition of Biofuels Marketing, Inc. discussed in Note 12 – Acquisitions, Divestitures and Joint Ventures below. Therefore all stock option expense was classified as general and administrative expense.



15



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



As of September 30, 2009, total unrecognized compensation expense under ASC Section 715-20-50 was $591,333, net of estimated forfeitures, which the Company will amortize over the next five fiscal years.

In January 2006, the Company issued certain employees 4,400,000 shares of common stock at $0.0025 per share in the form of restricted stock awards in connection with employment agreements under restricted unit purchase agreements. These shares were issued as an incentive to retain key employees and officers and vest over 3 years.

The following table summarizes the Company’s repurchase rights under these agreements:

 

 

Number of

Shares

 

 

Weighted

Average Grant

Date Fair

Value

 

Repurchasable shares as of December 31, 2008

 

 

250,000

 

 

 

0.0025

 

Vested

 

 

(250,000

)

 

 

(0.0025

)

Forfeited

 

 

––

 

 

 

––

 

Repurchasable shares as of September 30, 2009

 

 

––

 

 

$

––

 

12. Acquisitions, Divestitures and Joint Ventures.

Marketing Company Acquisition. On September 1, 2007, we acquired Biofuels Marketing, Inc., a Nevada corporation, in exchange for 200,000 shares of common stock valued at $3.00 per share. Of the shares issued, 50% were contingent upon the continued employment of the President of Biofuels Marketing through August 31, 2009, and are accounted for as compensation expense as earned. Of the purchase price, $300,000 was assigned to the primary asset acquired, which was a customer list, which was amortized over 18 months.

Technology Company Formation. On February 28, 2007, we acquired a 51% interest in Energy Enzymes, Inc. We have the right to acquire the remaining 49% for 1,000,000 shares of our common stock upon the fulfillment of certain performance milestones. The performance milestones had not been met as of September 30, 2009. In accordance with ASC Section 810-10-65, we attributed net loss to Energy Enzymes, Inc. beginning at the date of adoption of ASC Section 810-10-65 in our consolidated statement of operations and recorded the minority interest to non-controlling interest in the stockholders equity section of our balance sheet. The equity attributable to the Company and to the non-controlling interest in Energy Enzymes, Inc. is as follows:

 

 

For the nine months ended September 30, 2009

 

 

For the nine months ended September 30, 2008

 

 

 

Parent

 

 

Noncontrolling Interest

 

 

Consolidated

 

 

Parent

 

 

Noncontrolling

Interest

 

Consolidated

 

December 31,
Accumulated deficit

 

$

(1,426,633

)

 

$

––

 

 

$

(1,426,633

)

 

$

(257,760

)

 

$

––

 

$

(257,760

)

Attributable net loss

 

 

(305,905

)

 

 

(293,891

)

 

 

(599,776

)

 

 

(916,159

)

 

 

––

 

 

(916,159

)

September 30,
Accumulated 
deficit

 

$

(1,732,538

)

 

$

(293,891

)

 

$

(2,026,409

)

 

$

(1,173,919

)

 

$

––

 

$

(1,173,919

)

Operating Agreement. In November 2008, we entered into an operating agreement with Secunderabad Oils Limited (“Secunderabad”). Under this agreement Secunderabad agreed to provide us with plant operational expertise on an as-needed basis and working capital, on an as needed basis, to fund the purchase of feedstock and other raw materials for our Kakinada biodiesel facility. Working capital advances bear interest at the actual bank borrowing rate of Secunderabad. In return, we agreed to pay Secunderabad an amount equal to 30% of the plant’s monthly net operating profit. In the event that our biodiesel facility operates at a loss, Secunderbad owes the Company 30% of the losses. The agreement can be terminated by either party at any time without penalty. During the three and nine months ended September 30, 2009, the Company paid Secunderabad approximately $112,260 and $192,394, respectively, under the agreement and approximately $52,793 and $60,239, respectively, in interest for



16



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



working capital funding. At September 30, 2009 and December 31, 2008 the Company had $423,896 and $0 outstanding under this agreement, respectively, and included as current short term borrowings on the balance sheet.

13. Segment Information.

Summarized financial information by reportable segment for the three and nine months ended September 30, 2009, based on the internal management system, is as follows:

Statement of Operations Data

 

For the three

months ended

September 30,

2009

 

 

For the nine

months ended

September 30,

2009

 

Revenues

 

 

 

 

 

 

India

 

$

4,054,985

 

 

$

7,552,938

 

North America

 

 

––

 

 

 

 

 

Other

 

 

––

 

 

 

 

 

Total revenues

 

$

4,054,985

 

 

$

7,552,938

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

 

 

 

 

 

 

 

India

 

$

3,685,366

 

 

$

7,101,076

 

North America

 

 

––

 

 

 

 

 

Other

 

 

––

 

 

 

 

 

Total cost of goods sold

 

$

3,685,366

 

 

$

7,101,076

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

 

 

 

 

 

 

India

 

$

369,619

 

 

$

451,862

 

North America

 

 

––

 

 

 

 

 

Other

 

 

––

 

 

 

 

 

Total gross profit

 

$

369,619

 

 

$

451,862

 

During the three and nine months ended September 30, 2009 all of our revenues were from sales to external customers in our India segment.

Balance Sheet Data

 

September 30,

2009

 

Total Assets

 

 

 

India

 

$

16,336,608

 

United States

 

 

3,274,934

 

Other

 

 

149,463

 

Total Assets

 

$

19,761,005

 

One customer represented 77% of our revenues for the three months ended September 30, 2009. Two customers, each individually representing more than 10% of revenues, represented 49% of our revenues for the nine months ended September 30, 2009. No other single customer represented more than 10% of our revenues during this period.

14. Related Party Transactions.

Laird Cagan, a former member of the Company’s board of directors and a significant stockholder, provides the Company a $5,000,000 secured revolving line of credit. At September 30, 2009, a total of $3,342,992 plus accrued interest of $307,827 was outstanding under this credit facility which accrues interest at 10% interest per annum. All outstanding principal and accrued interest is due and payable on July 1, 2011.



17



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



The Company and Eric A. McAfee, the Company's Chief Executive Officer and Chairman of the board of directors, are parties to an agreement pursuant to which the Company pays Mr. McAfee a monthly salary of $10,000 per month for services rendered to the Company as its President and CEO. For each of the three and nine months ended September 30, 2009 and 2008, the Company paid or accrued Mr. McAfee $30,000 and $90,000, respectively, pursuant to this agreement. As of September 30, 2009, the Company owes Mr. McAfee $130,000 under the terms of this agreement.

The Company and CM Consulting are parties to an agreement pursuant to which the Company reimbursed CM Consulting for a minimum of 20 hours per month of time on an aircraft owned by CM Consulting until February 2008. The Company paid an upfront fee of $360,000 in February 2006 for 24 months of usage. The contract expired in February 2008. The Company expensed $30,000 of this rental fee for the nine months ended September 30, 2008. Eric A. McAfee, a director, officer and significant shareholder of the Company owns 50% of CM Consulting.

The Company and Cagan McAfee Capital Partners are parties to an agreement pursuant to which Cagan McAfee Capital Partners provides administrative and advisory services for a monthly fee of $15,000 plus expense reimbursement to the Company. For the three and nine months ended September 30, 2009, the Company paid Cagan McAfee Capital Partners $45,418 and $101,089, respectively. For the three and nine months ended September 30, 2008, the Company paid Cagan McAfee Capital Partners $10,995 and $89,327, respectively. Eric A. McAfee, an officer and member of the Company’s board of director and Laird Cagan, a former of the Company’s board of directors, together own 100% of Cagan McAfee Capital Partners. The contract expired in January 2009. As of September 30, 2009, the Company owes Cagan McAfee Capital Partners $209,866 under the terms of this agreement.

The Company is billed by McAfee Capital for certain expense reimbursements, principally in connection with services provided by Eric A. McAfee and his administrative personnel. For the three and nine months ended September 30, 2009, the Company paid McAfee Capital $12,526 and $20,443, respectively. Eric A. McAfee, an officer and member of the Company’s board of director, owns 100% of McAfee Capital. The Company owes McAfee Capital $17,943 under the terms of this arrangement.

TIC - The Industrial Company (TIC) and Delta-T are companies involved in the design and construction of ethanol plants in the United States. In 2006 the Company paid TIC and Delta-T approximately $7.5 million for services related to the design and initial construction work on the Company’s Sutton ethanol plant facility. In August 2007, the Company and TIC ended their relationship, and the company wrote off approximately $5.2 million in design work and construction in progress. On October 6, 2008, the Company and TIC cancelled their Strategic Alliance Agreement and TIC agreed to return 4,000,000 shares of the Company’s common stock for a total payment of $500,000 by the Company. Upon cancellation of the agreement, TIC returned 1,880,000 shares and will return the remaining 2,120,000 shares upon the receipt of the final payment. The final payment was not made as required on December 30, 2008 and interest is accruing at the annual rate of 18% until paid in full.

In July, 2009, the Company entered into a sublease agreement with Solargen Energy, Inc. for approximately 3,000 square feet of leased space. Eric McAfee, member of the Company’s board of directors and a significant stockholder, is also a member of the Board of Directors and a significant shareholder of Solargen, Energy, Inc. Michael Peterson, a member of the Company’s board of directors is also the Chief Executive Officer of Solargen, Energy, Inc. For the three months ended September 30, 2009, the Company invoiced, collected and offset as rent expense $21,418 under this agreement. The future minimum lease payments above exclude collections of rent under this sublease agreement. See Note 8 Operating Leases.

15. Income Tax.

The Company files a consolidated federal income tax return. This return includes all corporate companies 80% or more owned by the Company as well as the Company’s pro-rata share of taxable income from pass-through entities in which Company holds an ownership interest. Energy Enzymes, Inc. is 51% owned by the Company, files a separate federal income tax return and is 100% consolidated for financial reporting. State tax returns are filed on a consolidated, combined or separate basis depending on the applicable laws relating to the Company and its subsidiaries.



18



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



We do not provide for U.S. income taxes on the undistributed earnings of our foreign subsidiaries, as we consider these to be permanently reinvested in the operations of such subsidiaries. At September 30, 2009, these undistributed losses totaled approximately $3,689,041. If any future earnings were distributed, some countries may impose withholding taxes. However, due to the Company’s overall deficit in foreign cumulative earnings and U.S. loss provision, we do not believe the net unrecognized U.S. deferred tax liability is material.

We adopted the provisions of ASC Topic 740-10 (formerly FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109”), on January 1, 2007. The adoption of FIN 48 had no impact on our financial statements. FIN 48 clarifies the accounting for uncertainty in income tax positions. FIN 48 provides that the tax effects from an uncertain tax position can be recognized in our financial statements only if the position is more-likely-than-not of being sustained on audit, based on the technical merits of the position. Tax positions that meet the recognition threshold are reported at the largest amount that is more-likely-than-not to be realized. This determination requires a high degree of judgment and estimation. We periodically analyze and adjust amounts recorded for our uncertain tax positions, as events occur to warrant adjustment, such as when the statutory period for assessing tax on a given tax return or period expires or if tax authorities provide administrative guidance or a decision is rendered in the courts.

We conduct business globally and, as a result, one or more of our subsidiaries file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world, including such major jurisdictions as India, Mauritius, and the United States. With few exceptions, we incorporated in 2006 and we are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations for years before 2006.

16. Contingent Liabilities.

On March 28, 2008, the Cordillera Fund, L.P. ("Cordillera") filed a complaint in the Clark County District Court of the State of Nevada against American Ethanol, Inc. and the Company. The complaint sought a judicial declaration that Cordillera has a right to payment from the Company for its American Ethanol shares at fair market value pursuant to Nevada's Dissenters' Rights Statute, a judicial declaration that Cordillera is not a holder of Series B preferred stock in the Company under the provisions of the statute; and a permanent injunction compelling the Company to apply the Dissenters' Rights Statute to Cordillera's shares and reimburse Cordillera for attorneys fees and costs. On or about October 7, 2009, the Court set the price of AE Biofuels, Inc. stock at $3.00 per share plus attorney fees to Cordillera plus accrued interest at the statutory rate of 5% from the date of merger. The time to appeal this decision has not yet run. See Note 9 – Stockholders Deficit.

On May 1, 2009 our transfer agent, Corporate Stock Transfer, Inc. (“CST”), filed a Complaint for Interpleader in the United States District Court for the District of Colorado. The interpleader action is based on the Company’s and CST’s refusal to remove the restrictive legend from a certificate representing 5,600,000 shares of the Company's restricted common stock (the “Certificate”) held by Defendant Surendra Ajjarapu and seeks a judicial determination as to whether the legend can be lawfully removed from the Certificate. On July 1, 2009 Defendant Ajjarapu answered the Complaint for Interpleader, and Cross-Claimants and Counter-Claimants Surendra Ajjarapu and Sandhya Ajjarapu (the “Ajjarapus”) cross-claimed against the Company for breach of fiduciary duty, conversion, violation of Section 10(b) of the Exchange Act and Rule 10b-5 and injunctive relief. The Ajjarapus also counter-claimed against CST for declaratory judgment. The Company does not believe it has any liability for the matters described in this litigation and intends to defend itself vigorously. However, there can be no assurance regarding the outcome of the litigation. An estimate of possible loss, if any, or the range of loss cannot be made and therefore we have not accrued a loss contingency related to these actions.

In June 2009, UBPL, our India subsidiary, exited from the Export Oriented Unit (EOU) taxation status and became a domestic producer under the Export Promotion Capital Goods (EPCG) taxation system. As part of the movement from the EOU to the EPCG taxation systems, the Company is required to export approximately $4,000,000 of biodiesel into the international markets before June 2017. This export requirement is an offset by the government of India for capital goods that were imported duty free during the construction of the biodiesel plant. Failure to export this product will result in the payment of tax on the portions remaining to be exported.  To date we exported approximately $2,875,000 under the EPCG taxation system in satisfaction of this requirement.



19



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



17. Fair Value Measurement.

Fair value, as defined in ASC Topic 820-10, is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of an asset should reflect its highest and best use by market participants, whether using an in-use or an in-exchange valuation premise. The fair value of a liability should reflect the risk of nonperformance, which includes, among other things, the Company’s credit risk.

Valuation techniques are generally classified into three categories: the market approach; the income approach; and the cost approach. The selection and application of one or more of the techniques requires significant judgment and are primarily dependent upon the characteristics of the asset or liability, the principal (or most advantageous) market in which participants would transact for the asset or liability and the quality and availability of inputs. Inputs to valuation techniques are classified as either observable or unobservable within the following hierarchy:

Level 1 Inputs

These inputs come from quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 Inputs

These inputs are other than quoted prices that are observable, for an asset or liability. This includes: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 Inputs

These are unobservable inputs for the asset or liability which require the Company’s own assumptions.

As required by ASC Topic 820-10, financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.

Our only financial asset carried at fair value is cash held in commercial bank accounts with short term maturities. We consider the statement we receive from the bank as a quoted price (Level 1 remeasurement) for cash and measure the fair value of these assets using the bank statement.

The Company’s financial liabilities include short and long-term debt and long term debt (related party). The carrying value of the Company’s short-term debt approximates fair value due to the short-term maturity of this instrument, which based on the pending amendment with Third Eye Capital ABL Opportunities Fund at the same interest rate as the current debt has a maturity date of December 2009 (Level 2 re-measurement) and which based on the operating agreement with Secunderabad Oils Limited at the actual borrowing rate of Secunderabad (Level 2 re-measurement). The Company’s long-term debt carrying value approximates fair value based upon the borrowing rates currently available to the Company for bank loans in India with similar terms and maturities (Level 2 re-measurement). The Company is unable to estimate the fair value of the long term debt (related party) due to the unsecured nature of this loan and the lack of comparable available credit facilities (Level 3 re-measurement).



20



AE BIOFUELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)



The carrying amounts and fair values of the Company’s financial instruments at September 30, 2009, are as follows:

 

 

 

 

 

 

Fair Value Measurements

 

 

 

Carrying

Amount

at September 30,
2009

 

 

Level 1

 

 

Level 2

 

Level 3

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and time deposits

 

$

107,631

 

 

$

107,631

 

 

$

––

 

$

––

 

Other Assets - Restricted Cash

 

 

 

 

 

 

 

 

 

 

––

 

 

––

 

Total

 

$

107,631

 

 

$

107,631

 

 

$

––

 

 

––

 

 

 

 

 

 

 

 

 

 

 

 

––

 

 

––

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term borrowings

 

$

(6,242,265

)

 

$

––

 

 

$

(6,242,265

)

$

––

 

Current portion of long-term debt

 

 

(4,084,013

)

 

 

––

 

 

 

(4,084,013

)

 

––

 

Current portion of long-term debt (related party)

 

 

(3,650,819

)

 

 

––

 

 

 

––

 

 

(3,650,819

)

Total

 

$

(13,977.097

)

 

$

––

 

 

$

(10,326,278

)

$

(3,650,819

)

18. Subsequent Events.

Our Company has evaluated and disclosed any subsequent events that have occurred from September 30, 2009 through November 5, 2009, the date of filing of this Quarterly Report on Form 10-Q. We were not required to recognize the effect of our subsequent events in our financial statements, as they arose after our balance sheet date. The following is a summary of our nonrecognized subsequent events:

Revolving line of credit – related party. During October and November, 2009, the Company borrowed an additional $300,000 under the $5,000,000 revolving line of credit facility provided by Laird Cagan, a former director and significant shareholder. See Notes 7 and 14 above.

On October 22, Eric A. McAfee assumed the liabilities of The Crone Law Group in the amount of approximately $114,541 as part of a private transaction between Mr. McAfee and The Crone Law Group.

On October 14, 2009 we extended our lease in Butte, Montana by signing a month to month lease on the same payment terms as our previous lease. We did not exercise our option to purchase the land and building at the original lease termination date, October 14, 2009.



21





Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations.

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is provided in addition to the accompanying consolidated financial statements and notes to assist readers in understanding our results of operations, financial condition, and cash flows. MD&A is organized as follows:

·

Overview. Discussion of our business and overall analysis of financial and other highlights affecting the Company to provide context for the remainder of MD&A.

·

Results of Operations. An analysis of our financial results comparing the three months ended September 30, 2009 to the three months ended September 30, 2008 and the nine months ended September 30, 2009 to the nine months ended September 30, 2008.

·

Liquidity and Capital Resources. An analysis of changes in our balance sheets and cash flows, and discussion of our financial condition.

·

Critical Accounting Estimates. Accounting estimates that we believe are important to understanding the assumptions and judgments incorporated in our reported financial results and forecasts.

The following discussion should be read in conjunction with the AE Biofuels, Inc. consolidated financial statements and accompanying notes included elsewhere in this report. The following discussion contains forward-looking statements that reflect the plans, estimates and beliefs of AE Biofuels, Inc. The actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Report, particularly under “Part II — Other Information, Item 1A. Risk Factors”, and in other reports we file with the Securities and Exchange Commission (“SEC”), specifically the most recent Annual Report on Form 10-K and 10-K/A.” All references to years relate to the calendar year ended December 31 of the particular year.

Overview

The Company’s goal is to be a leader in the production of next-generation fuels to meet the increasing demand for renewable transportation fuels, and to reduce dependence on petroleum-based energy sources in an environmentally responsible manner. We have raised approximately $31.8 million to date through the sales of our preferred stock and approximately $13 million through debt facilities to fund our operations since our inception in late 2005. To date, we have used these funds to (i) construct and operate a 50 MGY biodiesel manufacturing facility in Kakinada, India, (ii) purchase land and land options for the development of ethanol and/or next generation ethanol plants in the United States (iii) develop, draft and submit three patents on proprietary, patent-pending enzyme technology, (iv) construct a portion of a glycerin refining and vegetable oil pretreatment facility at our Kakinada plant, and (v) commercialize our proprietary, patent-pending enzyme technology, including the construction and operation of our next-generation cellulose ethanol demonstration facility in Butte, Montana.

We completed construction of both our biodiesel plant and our cellulosic ethanol demonstration plant in 2008 and we have been selling biodiesel since November 2008. We, however, currently do not have sufficient cash reserves to meet our anticipated operating and capital obligations. As a result, we are in the process of seeking additional capital for operation of our Kakinada refinery at full capacity, for continuing the construction of the glycerin refining and vegetable oil pretreatment plant, for funding development activities at our cellulosic ethanol demonstration plant, for operating an ethanol plant in California, and for paying ongoing corporate overhead expenses. The amount of additional capital we raise will have to be sufficient to fund the working capital of the biodiesel plant until the plant generates sufficient cash flow from operations, if ever. Further, we have been operating at a loss and expect to increase our operating expenses significantly as we expand our operations.

The worldwide market for biofuels continued to grow in 2008 and 2009 and we have benefited from the growth of biodiesel use domestically in India as we began our operations and sales of biodiesel into the domestic Indian market in November 2008. Our revenues during the period covered by this Report consist of sales of biodiesel to a customer in Europe, sales of glycerin to customers in India and sales of biodiesel to retail distributors in India. We receive the order and payment on the majority of our sales before distribution of the product. Payment on sales to customers outside of India are in the form of non-recourse secured letters of credit. We sell our product primarily through outside sales brokers and partially through an inside sales force. We have not sold products on a consignment basis and during the three months ended September 30, 2009 we made our first export sale. We have



22





the ability to generate additional revenue through the sale of crude glycerin, the by-product from the biodiesel production process. During the nine months ended September 30, 2009 we sold 1,454 metric tons of crude glycerin. We are in the process of raising capital in order to complete our glycerin refinery at our Kakinada plant. We had no sales of glycerin in fiscal 2008. Our cost of revenues consists of feedstock, chemicals and plant overhead. Depending upon the costs of these products in comparison to the sales price of the biodiesel, our gross margins can vary from positive to negative. Overhead expenses include direct and indirect costs associated with the biodiesel production at our Kakinada plant, plant utilities, maintenance, insurance, depreciation and freight. We produced 10,982 metric tons of biodiesel in 2009 and sold 11,163 metric tons of biodiesel which was 10.4% of our total plant capacity for the nine months ended September 30, 2009.

In August 2008, we opened the first integrated cellulose and starch ethanol commercial demonstration facility in the United States. Our 9,000 square foot demonstration plant is capable of producing ethanol from a variety of feedstock sources, including wheat straw and corn stover. Our integrated technology addresses the requirement for commercially viable uses of non-food feedstock to complement existing feedstock sources to meet the worldwide demand for ethanol. Our strategy for the commercialization of our integrated cellulose and starch process includes: (i) acquiring existing starch (corn) ethanol plants and retrofitting them with our cellulosic technology; (ii) establishing joint ventures with existing ethanol plants (including corn ethanol plants in the U.S. and sugarcane ethanol plants in Brazil and India); (iii) constructing and operating standalone cellulosic ethanol facilities; and (iv) licensing our proprietary technology to ethanol plants in the U.S., Europe, Brazil and India.

During the three and nine months ended September 30, 2009, we operated our biodiesel plant in India; however, our current operations are constrained by limited working capital and the lack of widespread market acceptance of biodiesel in India. We believe that we can continue to increase sales of biodiesel in 2009; however, the domestic Indian market must continue to increase acceptance of biodiesel our and the margins between the feedstock costs and the biodiesel sales price must remain positive in order for us to have positive gross margins in 2009. Our primary export market is Europe and we do not expect sales of biodiesel to increase in the fourth quarter of fiscal 2009 as palm-based biodiesel has poor cold temperature flowing properties and, therefore, is not sold into Europe during the winter. Therefore we expect some seasonality in our export shipments into Europe in our fourth quarter each fiscal year.

We expect the market for next generation cellulosic ethanol to continue to grow in the United States due to a focus toward reducing reliance on petroleum based fuel and due to increased cellulosic ethanol mandates specified by the updated Renewable Fuel Standard (RFS 2). At the outset of 2009, we believed that we could begin generating revenues through the commercialization of our cellulosic ethanol technology and associated Renewable Identification Number (RIN’s) in 2009; however, we have not been able to generate revenues from this technology thus far.

Our cash and cash equivalents balance was $107,631 as of September 30, 2009, of which $55,843 was held in our domestic entities and $51,788 was held in foreign subsidiaries. Our current ratio as of September 30, 2009 was 0.08 compared to a current ratio of 0.13 as of December 31, 2008. We ended September 30, 2009 with limited working capital resources and we will need to raise additional working capital in 2009 in order to achieve our goals in India and the U.S. Due to the global financial crisis during the past twelve months, obtaining working capital through commercial banks or through other means is a significant challenge and we cannot be assured we will be able to obtain additional working capital and therefore be successful in 2009. Should the Company not be able to raise enough equity or debt financing, it may be forced to sell all or a portion of its existing biodiesel facility or other assets to generate cash to continue the Company’s business plan or possibly discontinue operations.

Results of Operations

Three Months Ended September 30, 2009 Compared to Three Months Ended September 30, 2008

Revenues

For the three months ended September 30, 2009, $4,054,985 or 100% of our revenue was derived from the sale of biodiesel. Of these sales approximately $2,875,000 resulted from a single sale into the export market and the balance resulted from sales into the Indian domestic market. All revenue during 2009 is from our India geographic segment. No revenues were recorded for the three months ended September 30, 2008.



23





We recognize revenue upon shipment of product as payments are generally made in advance and we do not offer any right of return. On export orders, we deliver our product FOB shipping point and receive a non-recourse letter of credit at delivery. We had no accounts receivable as of September 30, 2009. Our average domestic sales transaction consists of a customer taking delivery of several metric tons of biodiesel by loading it into their tanker truck at our plant site. We have several domestic customers who take delivery of biodiesel on a daily basis. During the three months ended September 30, 2009 we made one export shipment of 4,125 metric tons to an international customer. Due to the seasonality of sales into the international markets, we expect that this order will be our only international order in 2009 and we do not expect any additional international orders until early 2010. As a result, it is difficult to predict timing or size of product sales on a quarterly basis.

Cost of Revenues

Our cost of revenues consists of fixed costs, including utilities, supplies, insurance, property taxes, depreciation and indirect labor compensation. Variable costs include direct labor compensation and direct material costs. The largest component of the cost of revenues is the palm oil or palm stearin feedstock for the biodiesel production process. The price of palm oil and palm stearin is influenced by general economic, market and regulatory factors. These factors include local and global supply and demand, weather conditions, farmer planting decisions, government policies and subsidies with respect to agriculture and international trade. The price at which we sell our biodiesel in India is generally indexed to the price of petroleum diesel, which is set by the Indian government, the lack of correlation between production costs and product prices means that we are generally unable to pass increased feedstock costs on to our customers. The cost of palm oil or palm stearin has fluctuated significantly in recent periods; however, for the three months ended September 30, 2009, the commodity markets proved to be more stable than they were in fiscal 2008. In early January 2009, we sold through all the feedstock purchased in 2008 and we are buying feedstock as required to support current biodiesel production. As a result of favorable feedstock prices and demand from an international customer, we were able to sell enough biodiesel to cover our costs of plant operations and repayment of working capital to Secunderabad. Our cost of revenues for the three months ended September 30, 2009 was smaller than our revenues and we generated a positive gross margin of $369,619 or 9.1%.

We exited the quarter ended September 30, 2009 with 781 metric tons of feedstock, which at current sales levels represents approximately two week of biodiesel sales. During the three months ended September 30, 2009, we recognized $101,549 in inventory adjustments attributable to lower of cost or market valuation. All of our cost of revenues was located in our India geographic segment. No revenues or cost of revenues were recorded for the three months ended September 30, 2008.

Expenses

Research and Development Expenses. The principal area of spending for research and development is our integrated cellulose and starch ethanol commercial demonstration facility in Butte. We incurred expense of $157,574 and $316,402 in the three month periods ended September 30, 2009 and 2008, respectively. The largest component of expense for the three months ended September 30, 2009 was $115,380 spent on salaries, wages and compensation as compared to zero spent in the three month period of the prior year. The second largest component of expense for the three months ended September 30, 2009 was $22,741 spent on rent, taxes and insurance on the facility as compared to $14,285 spent in the three month period of the prior year. We charged $17,571 of depreciation to research and development, as compared to $6,952 in the prior year. The balance of expenses for the three months ended September 30, 2009 was related to professional services and supplies. In the three month period ended September 30, 2008, we incurred $230,750 in supplies and services related to the build-out of our research and development facility in Butte, which was completed and commissioned in August 2008. All of our research and development expenses were incurred in the North America segment.

Selling, General and Administrative Expenses. Principal areas of spending for general and administrative spending are in the areas of employee compensation, professional services, travel, depreciation, and office expenses, including rent.



24





We summarize our spending within the North America segment into eight components as follows:

 

 

For the Three Months Ended

September 30,

 

 

 

2009

 

 

2008

 

 

 

%

 

 

%

 

Salaries, wages and compensation

 

 

55

 

 

 

54

 

Supplies and services

 

 

4

 

 

 

5

 

Repair and maintenance

 

 

––

 

 

 

––

 

Taxes, insurance, rent and utilities

 

 

13

 

 

 

7

 

Professional services

 

 

26

 

 

 

25

 

Depreciation and amortization

 

 

1

 

 

 

––

 

Travel and entertainment

 

 

1

 

 

 

3

 

Miscellaneous expense

 

 

––

 

 

 

6

 

Total

 

 

100

 

 

 

100

 

The single largest component of selling, general and administrative expense is employee compensation, including related stock compensation. For the three months ended September 30, 2009 and 2008, the number of United States employees remained flat at 12 employees. Compensation expense decreased from $870,978 for the three months ended September 30, 2008 to $478,122 for the three months ended September 30, 2009. The decrease was principally driven by a change in the mix of employees that includes fewer executive level employees and by lower non-cash, stock compensation of $137,631 for the three months ended September 30, 2009 compared to non-cash, stock compensation of $297,578 recorded during the same period of 2008.

The second largest component of selling, general and administrative expense is professional services, which include legal, accounting, financial advisory, board compensation, security filings, and transfer agent fees along with associated non-cash stock compensation expense. For the three months ended September 30, 2009, we spent $286,154 on professional services including a non-cash stock compensation charge of $16,004 for stock grants to key consultants and advisors. For the three months ended September 30, 2008, we spent approximately $410,741 on professional services of which a credit for $80,839 was posted as non-cash stock-based compensation. The decrease from the prior year is attributable to a reduction in spending on all professional fees, including legal and financial advisory fees.

The third largest component of selling, general and administrative expense is taxes, insurance, rent and utilities. This category also includes licenses and permits as well as penalties and interest. The taxes included in this item are non-income based taxes. For the three months ended September 30, 2009 most of the $138,347 was spent on rent, utilities and insurance. This level of spending is slightly higher than the $120,449 spent during the three months ended September 30, 2008 due to an increase in our insurance expenses in 2009 as compared to 2008.

During the three months ended September 30, 2009, we incurred some selling and marketing expenses related to our biodiesel sales, which consisted primarily of salaries, commissions and benefits related to sales and marketing personnel and sales brokers; travel and other out-of-pocket expenses, amortization of intangible assets related to our acquisition of Biofuels Marketing, Inc. and facilities costs and other related overhead. Commissions on biodiesel sales are typically accrued and expensed or paid when the respective products are sold. We intend to hire additional sales personnel, initiate additional marketing programs and build additional relationships with resellers and strategic partners on a global basis. Accordingly, we expect that our sales and marketing expenses will increase for the foreseeable future in absolute dollars. At this time, these costs are small and accordingly we have included them in general and administrative.



25





We summarize our spending within the India segment into eight components as follows:

 

 

For the Three Months Ended

September 30,

 

 

 

2009

 

 

2008

 

 

 

%

 

 

%

 

Salaries, wages and compensation

 

 

2

 

 

 

––

 

Supplies and services

 

 

73

 

 

 

––

 

Repair and maintenance

 

 

2

 

 

 

––

 

Taxes, insurance, rent and utilities

 

 

5

 

 

 

––

 

Professional services

 

 

5

 

 

 

––

 

Depreciation and amortization

 

 

6

 

 

 

––

 

Travel and entertainment

 

 

5

 

 

 

––

 

Miscellaneous expense

 

 

2

 

 

 

––

 

Total

 

 

100

 

 

 

––

 

During the early part of 2008, our India segment was fully engaged in the construction of the biodiesel plant in Kakinada, India. As such, substantially all costs associated with this segment were capitalized as costs associated with placing this asset in service. In October 2008, the plant was commissioned and operations commenced.

The largest component of selling, general and administrative expense is supplies and services expense of $237,519 principally associated with the operational support agreement with Secunderabad Oil. The second largest component is depreciation expense associated with biodiesel plant.

Other Income/Expense

Other income (expense) consisted of the following items:

·

Interest expense is the result of debt facilities acquired by both the Company and its India subsidiary and interest accrued on the complaint filed by Cordillera Fund, L.P. These debt facilities included warrant coverage and discount fees which are amortized as part of interest expense. Currently, two of the debt facilities accrue interest at the default rate of interest. We incurred interest expense of $692,714. During the same period of 2008 we incurred and capitalized $593,494 of interest and recorded zero interest expense.

·

Interest income is earned on excess cash. Due to low levels of cash during both the three months ended September 30, 2009, and the same period of 2008, our interest income remained at low levels of $6,565 and $58, respectively.

·

Other income, for both years, results from renting portions our land holdings in Sutton and Danville to local farmers and a sublease for office space at our Cupertino office.

Nine Months Ended September 30, 2009 Compared to Nine Months Ended September 30, 2008

Revenues

For the nine months ended September 30, 2009, $7,552,938 or 100% of our revenue was derived from the sale of biodiesel. Of these sales approximately $2,875,000 were made into the export market and the balance made into the Indian domestic market. All revenue during 2009 is part of our India geographic segment. No revenues were recorded for the nine months ended September 30, 2008.

We recognize revenue upon shipment of product as payments are generally made in advance and we do not offer any right of return. We had no accounts receivable as of September 30, 2009. Our average sales transaction consists of a customer taking delivery of several metric tons of biodiesel by loading it into their tanker truck at our plant site. During the three months ended September 30, 2009 we made one export shipment of 4,125 MT to an international customer which was funded using a non-recourse letter of credit. Due to the seasonality of sales into Europe, we expect that this order will be the last export order until early 2010. We have several customers who take domestic Indian delivery of biodiesel on a daily basis. As a result, it is difficult to predict timing or size of product sales on a quarterly basis.



26





Cost of Revenues

Our cost of revenues consists of fixed costs, including utilities, supplies, insurance, property taxes, depreciation and indirect labor compensation. Variable costs include direct labor compensation and direct material costs. The largest component of the cost of revenues is the palm oil or palm stearin feedstock for the biodiesel production process. The price of palm oil and palm stearin is influenced by general economic, market and regulatory factors. These factors include local and global supply and demand, weather conditions, farmer planting decisions, government policies and subsidies with respect to agriculture and international trade. The price at which we sell our biodiesel in India is generally indexed to the price of petroleum diesel, which is set by the Indian government, the lack of correlation between production costs and product prices means that we are generally unable to pass increased feedstock costs on to our customers. The cost of palm oil or palm stearin has fluctuated significantly in recent periods; however, for the nine months ended September 30, 2009, the commodity markets proved to be more stable than they were in fiscal 2008. In early January 2009, we sold through all the feedstock purchased in 2008 and we are buying feedstock as required to support current biodiesel production. During the nine months ended September 30, 2009 there was an increase in the price of palm oil or palm stearin to the point were the cost of production was higher than the cost of selling the biodiesel; therefore, we did not buy feedstock or produce and sell biodiesel for several weeks during the three months ended June 30, 2009. As a result of favorable feedstock prices and demand from an international customer, we were able to sell enough biodiesel to post a positive gross margin, yet we did not sell amounts of biodiesel with enough profit margin to cover our fixed costs of the biodiesel plant. For the nine months period ended September 30, 2009 our biodiesel sales and gross margins exceeded our fixed and variable cost of revenues and we recognized a gross profit of $451,862 or 6.0%..

We exited the quarter ended September 30, 2009 with 781 metric tons of feedstock, or about two week’s worth of biodiesel sales, at our current quarter’s sales levels. During the nine months ended September 30, 2009, we recognized $335,722 in inventory adjustments attributable to lower of cost or market valuation. All of our cost of revenues was located in our India geographic segment. Neither revenues nor cost of revenues were recorded for the nine months ended September 30, 2008.

Expenses

Research and Development Expenses. The principal area of spending for research and development is our integrated cellulose and starch ethanol commercial demonstration facility in Butte. We incurred expense of $399,148 and $828,458 in the nine month periods ended September 30, 2009 and 2008, respectively. The largest component of expense for the nine months ended September 30, 2009 was the $132,529 we spent on professional services primarily related to the salaries for the small team of scientists working at the Butte facility and for legal services associated with our pending patents, compared to $182,786 for the same period of the prior year. We spent $61,649 on rent, taxes and insurance on the facility as compared to $44,032 in the nine month period of the prior year. We charged $52,713 of depreciation to research and development, as compared to $11,093 in the prior year. For the nine months ended September 30, 2008, we incurred $570,342 in supplies and services related to the build-out of our of our research and development facility in Butte, which was completed and commissioned in August 2008. The balance of the research and development expenses in both the nine months ended September 30, 2009 and 2008 were for miscellaneous office expenses and travel. All of our research and development expenses were incurred in the North America segment.

Selling, General and Administrative Expenses. Principal areas of spending for general and administrative spending are in the areas of employee compensation, professional services, travel, depreciation, and office expenses, including rent.



27





We summarize our spending within the North America segment into eight components as follows:

 

 

For the Nine Months Ended

September 30,

 

 

 

2009

 

 

2008

 

 

 

%

 

 

%

 

Salaries, wages and compensation

 

 

50

 

 

 

45

 

Supplies and services

 

 

4

 

 

 

6

 

Repair and maintenance

 

 

––

 

 

 

––

 

Taxes, insurance, rent and utilities

 

 

12

 

 

 

6

 

Professional services

 

 

30

 

 

 

36

 

Depreciation and amortization

 

 

2

 

 

 

2

 

Travel and entertainment

 

 

2

 

 

 

5

 

Miscellaneous expense

 

 

––

 

 

 

––

 

Total

 

 

100

 

 

 

100

 

The single largest component of selling, general and administrative expense is employee compensation, including related stock compensation. For the nine months ended September 30, 2009 and 2008, the number of United States employees remained flat at 12 employees. Compensation expense decreased from $3,219,279 for the nine months ended September 30, 2008 to $1,801,035 for the nine months ended September 30, 2009. The decrease was driven by a change in the mix of employees that includes fewer executive level employees and a decrease in non-cash, stock compensation from $1,776,882 for the nine months ended September 30, 2008 compared to non-cash, stock compensation of $586,609 recorded during the same period of 2009.

The second largest component of selling, general and administrative expense is professional services, which include legal, accounting, financial advisory, board compensation, security filings, and transfer agent fees along with associated non-cash stock compensation expense which arose from stock awards granted to consultants and advisors. For the nine months ended September 30, 2009, we spent $1,074,030 on professional services including a non-cash stock compensation charge of $19,300 for stock grants to key consultants and advisors. For the nine months ended September 30, 2008, we spent approximately $2,613,885 on professional services of which $413,039 was stock-based compensation. The decrease from the prior year is attributable to a reduction in spending on all professional fees, including legal and financial advisory fees and lower non-cash stock based compensation charges, due to a lower price of our common stock at September 30, 2009 as compared to September 30, 2008.

The third largest component of selling, general and administrative expense is taxes, insurance, rent and utilities. This category also includes licenses and permits as well as penalties and interest. The taxes included in this item are non-income based taxes. For the nine months ended September 30, 2009 most of the $445,274 was spent on rent, utilities and insurance. This level of spending is relatively consistent with the $447,918 spent during the nine months ended September 30, 2008.

During the nine months ended September 30, 2009, we incurred some selling and marketing expenses related to our biodiesel sales, which consisted primarily of salaries, commissions and benefits related to sales and marketing personnel and sales brokers; travel and other out-of-pocket expenses, amortization of intangible assets related to our acquisition of Biofuels Marketing, Inc. and facilities costs and other related overhead. Commissions on biodiesel sales are typically accrued and expensed or paid when the respective products are sold. We intend to hire additional sales personnel, initiate additional marketing programs and build additional relationships with resellers and strategic partners on a global basis. Accordingly, we expect that our sales and marketing expenses will increase for the foreseeable future in absolute dollars. At this time, these costs are small and accordingly we have included them in general and administrative.



28





We summarize our spending within the India segment into eight components as follows:

 

 

For the Nine Months Ended

September 30,

 

 

 

2009

 

 

2008

 

 

 

%

 

 

%

 

Salaries, wages and compensation

 

 

3

 

 

 

––

 

Supplies and services

 

 

31

 

 

 

––

 

Repair and maintenance

 

 

3

 

 

 

––

 

Taxes, insurance, rent and utilities

 

 

9

 

 

 

––

 

Professional services

 

 

45

 

 

 

––

 

Depreciation and amortization

 

 

3

 

 

 

––

 

Travel and entertainment

 

 

5

 

 

 

––

 

Miscellaneous expense

 

 

1

 

 

 

––

 

Total

 

 

100

 

 

 

––

 

During the early part of 2008, our India segment was fully engaged in the construction of the biodiesel plant in Kakinada, India. As such, substantially all costs associated with this segment were capitalized as costs associated with placing this asset in service. As of October 2008, the plant was commissioned and operations commenced.

The largest component of selling, general and administrative expense is professional services, which include legal, accounting, financial advisory and technical services. For the nine months ended September 30, 2009, we spent $500,291 on professional services, which includes $73,017 paid to consultants in connection with our application for a change in taxation status of our biodiesel plant from an export oriented unit to a domestic production unit (the “Domestication”) and $358,169 to a legal firm in connection with fund raising.

The second largest component of selling, general and administrative expense is supplies and services, which include payments under the agreement with Secunderabad (see Note 12 – Acquisitions, Divestitures and Joint Ventures in the Notes to Consolidated Financial Statements), and office supplies and expenses. For the nine months ended September 30, 2009, we spent $342,002 in this category of which $192,394 was paid to Secunderabad.

The third largest component of selling, general and administrative expense is taxes, insurance, rent and utilities. For the nine months ended September 30, 2009, we spent $ 104,665 in this category, of which $50,643 was for duties related to the Domestication of the biodiesel plant.

Other Income/Expense

Other income (expense) consisted of the following items:

·

Pursuant to the terms of its Amended and Restated Registration Rights Agreement, beginning in January 2008 the Company was obligated to file a registration statement to register shares of common stock issued or issuable upon conversion of the Company's for Series A and B preferred stock or pay in cash or shares of stock to these investors an amount equal to 0.5% per month of their investment amount. The expense related to this payment from the period from January through December 2008 of $2,274,402 is reflected in our Statement of Operations as a registration rights payment.

·

During the nine months ended September 30, 2008, we purchased and resold glycerin. These sales resulted in profits of $78,276 on sales of $302,000. As we had not commenced commercial operations as of September 30, 2008, the profits from these sales are classified in other income.

·

On January 23, 2008, we agreed to end the joint venture with Acalmar Oils and Fats, Ltd. (“Acalmar”) including termination of Acalmar’s right to own or receive any ownership interest in the joint venture. The total cancellation price of $900,000 is reflected in our Statement of Operations as a shareholder agreement cancellation payment.

·

Interest expense is the result of debt facilities acquired by both the Company and its India subsidiary and interest accrued on the complaint filed by Cordillera Fund, L.P. These debt facilities included warrant coverage and discount fees which are amortized as part of interest expense. For the nine



29





months ended September 30, 2009 we incurred interest expense of $2,137,212. During the same periods of 2008 we incurred $253,020 of interest expense.

·

Interest income is earned on excess cash. Due to the decrease in our cash balances over the nine months ended September 30, 2009, as compared to the same period of 2008, our interest income decreased from $32,544 to $19,526.

·

Other income for both periods also arose from renting portions of our land holdings in Sutton and Danville to local farmers.

Income Taxes

Provision for income taxes is calculated in accordance with ASC Topic 740 (formerly Statement of Financial Accounting Standard No. 109, “Accounting for Income Taxes”), using an asset and liability approach. This approach requires the recognition of taxes payable or refundable for the current year and deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements or tax returns. The measurement of current and deferred taxes is based on provisions of enacted tax law.

ASC Topic 740 provides for recognition of deferred tax assets if the realization of such assets is more likely than not to occur. Otherwise, a valuation allowance is established for the deferred tax assets which may not be realized. As of September 30 and December 31, 2008 and 2007, the Company recorded a full valuation allowance against its net deferred tax assets due to operating losses incurred since inception. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets were fully offset by a valuation allowance.

The Company is subject to income tax audits by the respective tax authorities in all of the jurisdictions in which it operates. The determination of tax liabilities in each of these jurisdictions requires the interpretation and application of complex and sometimes uncertain tax laws and regulations. The recognition and measurement of current taxes payable or refundable and deferred tax assets and liabilities requires that the Company make certain estimates and judgments. Changes to these estimates or a change in judgment may have a material impact on the Company’s tax provision in a future period.

We adopted the provisions of ASC Topic 740 ( formerly FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109”), on January 1, 2007, and there was no impact to our financial statements. ASC Topic 740 clarifies the accounting for uncertainty in income tax positions. ASC Topic 740 provides that the tax effects from an uncertain tax position can be recognized in our financial statements only if the position is more-likely-than-not of being sustained on audit, based on the technical merits of the position. Tax positions that meet the recognition threshold are reported at the largest amount that is more-likely-than-not to be realized. This determination requires a high degree of judgment and estimation. We periodically analyze and adjust amounts recorded for our uncertain tax positions, as events occur to warrant adjustment, such as when the statutory period for assessing tax on a given tax return or period expires or if tax authorities provide administrative guidance or a decision is rendered in the courts. Furthermore, we do not reasonably expect the total amounts of unrecognized tax benefits to significantly increase or decrease within the next 12 months. As of September 30, 2009 and December 31, 2008, our unrecognized tax benefits were not significant.

Liquidity and Capital Resources

Contractual Obligations

In June 2009, our India subsidiary exited from the Export Oriented Unit taxation status and became a domestic producer. As part of the governmental agreements, the Company is required to export approximately $4,000,000 of biodiesel into the international markets before June 2017 or pay the tax as though the exported biodiesel was sold within the country of India. We do not have any other material off-balance sheet arrangements nor do we have any other material changes with respect to our contractual obligations.



30





Liquidity

Cash and cash equivalents, current assets, current liabilities and debt at the end of each period were as follows:

 

 

September 30,

2009

 

 

September 30,

2008

 

Cash and cash equivalents

 

$

107,631

 

 

$

591,718

 

Current assets (including cash and cash equivalents)

 

 

1,482,626

 

 

 

2,322,431

 

Current liabilities (including short term debt)

 

 

21,410,903

 

 

 

9,471,568

 

Short and long term debt

 

$

13,977,097

 

 

$

9,645,854

 

The Company has experienced losses and continues to have negative cash flows from its operations through September 30, 2009. As noted in the table above, the Company has negative working capital (current assets less current liabilities). To date, our operating biodiesel plant has provided us with only minimal cash flow, and it will likely be insufficient to allow for the completion of our business plan in 2009. As the development of our business plan has taken longer to develop than we had forecasted, we may have to review our long lived assets for impairment at a future date. Funds available at September 30, 2009 are sufficient to cover less than one month of our domestic operating costs.

In order for us to continue as a going concern, we require a significant amount of additional working capital to fund our ongoing operating expenses and future capital requirements. The use of additional working capital is primarily for general and administrative expenses, the purchase of feedstock and other raw materials to operate our existing facilities and debt interest and principal payments. Our ability to identify and enter into commercial arrangements with feedstock suppliers in India depends on maintaining our operations agreement with Secunderabad, who is currently providing us with working capital for our Kakinada facility. If we are unable to maintain this strategic relationship, our business may be negatively affected. In addition, the ability of Secunderabad to continue to provide us with working capital depends in part on the financial strength of Secunderabad and its banking relationships. If Secunderabad is unable or unwilling to continue to provide us with working capital, our business may be negatively affected.

With regards to our $5,000,000 senior secured note held by Third Eye Capital ABL Opportunities Fund (which had a carrying value at September 30, 2009 of $5,818,369), we were not in compliance with the current ratio covenant for the months of November 2008 through September 2009 under the loan agreement nor were we in compliance with the stock market capitalization covenant for December 2008 through September 2009. Prior to the note maturing on May 15, 2009, the Company entered into an amendment and limited waiver (the “Amendment”) with Third Eye Capital Corporation (“Agent”) on behalf of itself and the Purchaser dated March 31, 2009. The Amendment had not become effective as of September 30, 2009 as we were unable to meet the conditions of effectiveness set forth in the Amendment. Accordingly, the interest rate under this facility has been accrued at the default interest rate, which is 18%, during the period of default.

The Company was not in compliance with the current ratio or stock market capitalization covenant for the months of November 2008 through September 2009 under the loan agreement. Due to the fact that our non-compliance with covenants has put our note into default, we have increased the interest rate on the note to the default interest rate of 18%, through September 30, 2009. The Company has no cross default provisions in this or any other debt agreement. As a result, our inability to execute the conditions of effectiveness of the Amendment will have no adverse impact on our other debt obligations. On August 11, 2009, the Company received a notice of default under the Note and Warrant Purchase Agreement asserting that the Company failed to maintain its current ratio and stock market capitalization covenants and as a result Events of Default have occurred and are continuing. The notice of default demands repayment of the entire outstanding indebtedness of $5 million together with all accrued interest thereon and any applicable fees and expenses. We are currently in discussions with the Purchaser with regards to an amendment to the Note and Warrant Purchase Agreement for the modification of terms. 

On October 7, 2009, UBPL received a demand notice from the State Bank of India. The notice informs UBPL that an event of default has occurred for failure to make an installment payment on the loan due in June, 2009 and demands repayment of the entire outstanding indebtedness of 19.60 crores (approximately $4 million) together with all accrued interest thereon and any applicable fees and expenses by October 10, 2009. Upon the occurrence and during the continuance of an Event of Default, interest accrues at the default interest rate of 2% above the State Bank Advance Rate pursuant to the Agreement of Loan for Overall Limit. The default period began on July 1, 2009



31





when the principal payment was deemed past due; therefore, we have accrued for the liquidating damages for the period of default in July and August. Additional provisions of default include the bank having the unqualified right to disclose or publish our company name and our directors names as defaulter in any medium or media. At the bank’s option, it may also demand payment of the balance of the loan since the principal payments are in default in July 2009 so we have classified the entire loan amount as current.We are currently in discussions with the Purchaser with regards to an amendment to the Note and Warrant Purchase Agreement for the modification of terms. If we are unsuccessful with our negotiations and there is an immediate acceleration of the payment of the entire principal balance, it would have a significant adverse impact on the Company’s near term liquidity and ability to operate our business in India.

Effective for the pay period ended February 28, 2009, two of our executive officers and five other employees voluntarily accepted compensation deferral for all of their salary, except that portion mandated by the Federal Wage and Hour laws. As of September 30, 2009, the deferral of their salaries has provided approximately $470,000 of reduced cash flow requirements to the Company. The repayment of these amounts will be a use of cash in the future.

Planned capital expenditures include an expected $1,000,000 to complete the pre-treatment facility and glycerin refinery at our Kakinada plant. Commitments for approximately $9,173 under construction contracts, purchase orders and other short term contracts were outstanding at September 30, 2009. We anticipate that the cash flow from our India operations will fulfill the current commitments and we expect to obtain an additional line of credit in India to provide us with the $1,000,000 required to complete our pre-treatment facility and glycerin refinery.

On August 17, 2009, International Biodiesel, Inc., a wholly owned subsidiary of AE Biofuels, Inc., entered into a Revolving Line of Credit Agreement with Laird Q. Cagan, a former member of the Company’s board of directors and a significant stockholder (the “Lender”), for $5,000,000. The Revolving Line of Credit is secured by accounts, investments, intellectual property, securities and other collateral of AE Biofuels, Inc. excluding the collateral securing the Company’s obligations under the Note and Warrant Purchase Agreement with Third Eye Capital Corporation and Third Eye Capital ABL Opportunities Fund. The Revolving Line of Credit bears interest at the rate of 10% per annum and matures on July 1, 2011, at which time the outstanding advances under the Revolving Line of Credit together with any accrued interest and other unpaid charges or fees will become due. Upon certain events, one of which is the default on any other debt facility, the Lender may declare a default upon 10 days prior written notice. Upon an event of default, the Lender may accelerate the outstanding indebtedness together with all accrued interest thereon and demand immediate repayment. The Company used the new Revolving Line of Credit Agreement to pay down the revolving line of credit facility with a limit of $3,500,000. The result of putting the new Revolving Line of Credit Agreement, dated August 17, 2009, was a $1,500,000 increase in the amount available to the Company, net of the paydown of the previous revolving line of credit, dated November 16, 2006.

We may continue to deploy our management team’s combined industry, technical, merger and acquisition (“M&A”), restructuring and corporate finance expertise to target and acquire undervalued and/or distressed assets, and then apply our technology to improve the performance of those assets. We believe that our strategy offers substantial opportunity to build capital value in the current climate, particularly given (a) the present opportunity to acquire undervalued and/or underperforming assets and improve them; and (b) the medium to longer term outlook for ethanol and cellulosic ethanol as an alternative form of energy is likely to lead to under supply in 2010. To effect the planned M&A strategy in full, the Company requires access to substantial further acquisition and development finance and it is currently working with advisers with a view to securing additional financing. This may be made available through industry and/or financial partnerships and joint ventures, special purpose financing vehicles, structured acquisition finance arrangements, private placements of equity, debt and blended debt and equity instruments. In addition, the Company anticipates that it may issue share and/or loan capital to vendors as a means of securing target acquisitions and to fund development.

We intend to raise additional working capital in 2009 through some of all of the following: operating cash flows, working capital lines of credit, long-term debt facilities, joint venture arrangements and the sale of additional equity by the Company or its subsidiaries. We continue to explore different funding sources, but because of the continued unsettled state of the capital markets around the globe, the Company lacks any defined capital raising projects or specific sources of capital or commitments for the required capital. The Company, in common with most enterprises that require capital to develop and implement their strategy, are challenged by the impact the crisis in the global capital markets is having on its ability to finance its plans. To a significant degree, our business success will



32





depend on the state of the capital markets, and investors in our securities should take into account the macro-economic impact of the availability of credit and capital funding when assessing the business development plans of the Company. Should the Company not be able to raise enough capital it may be forced to sell all or a portion of its existing biodiesel facility or other assets at a discount to market value and incur impairment related to these assets to generate cash to continue the Company’s business plan or possibly discontinue operations. Subsequent to September 30, 2009, we drew down short term borrowings from our line of credit with Laird Cagan totaling $171,000 to meet some of our 2009 operating costs, however, to continue operations the Company needs to secure additional near term equity or debt financing. Until such additional capital is raised, the Company is dependent on financing from this related party and the arrangement of extended term with our trade creditors. There can be no assurance that additional financing will be available on terms satisfactory to the Company. The accompanying financial statements do not include any adjustments that may result should the Company be unable to continue as a going concern.

Historical Sources and Uses of Cash

Operating Activities

Net cash used in operating activities for the nine months ended September 30, 2009 was $1,930,224 primarily from selling, general and administrative expenses and research and development expense offset by gross profits from operations of $451,862 and decrease in working capital of $8,581,123 principally from the reclassification of long term debt. The generation of cash from working capital arose principally from the aging of our accounts payable and aging of interest and accruing fees on our debt facilities. Net cash used in operating activities for the same nine months of fiscal 2008 was $7,299,880 primarily to develop our business, including general and administrative and research and development costs. Net cash used in operating activities was lower in the current year as compared to the prior year period due to reduced spending in all areas including professional services, salaries, supplies and services and travel. The increase in accounts payable in 2009 decreased use in cash due to delayed payments to vendors during the nine months ended September 30, 2009.

Investing Activities

Net cash used in investing activities during the nine months ended September 30, 2009 was $78,978, which consisted primarily of purchases of property, plant and equipment relating to our biodiesel facility in India. For the nine months ended September 30, 2008, net cash used by investing activities of $3,048,936 consisted primarily of purchases of property, plant and equipment relating to the construction of our biodiesel facility in India and the construction of our cellulosic demonstration plant in Butte, Montana. Offsetting this amount was the $2,568,216 provided by the redemption of time deposits and $500,000 from the release of a restricted letter of credit.

Financing Activities

Net cash provided by financing activities during the nine months ended September 30, 2009 and 2008 was $1,729,416, and $10,133,243, respectively, which consisted primarily of the proceeds from our working capital line with Secunderabad and the proceeds from the Revolving Line of Credit Agreement, dated August 17, 2009 provided by a related party (a former director and significant shareholder) for the nine months ended September 30, 2009 and from proceeds of the $5 million senior secured note from Third Eye Capital and from the proceeds of the $4.1 million term loan from State Bank of India for the nine months ended September 30, 2008.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of net sales and expenses for each period. The following represents a summary of our critical accounting policies, defined as those policies that we believe are the most important to the portrayal of our financial condition and results of operations and that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain.



33





Impairment of Long-Lived Assets

Our long-lived assets are primarily associated with our plant in Kakinada, India. In fiscal 2008, we began operation of our biodiesel plant and we continued the construction of our glycerin refinery and pre-treatment plant. The refinery and pre-treatment plant are expected to be fully operational by the third quarter of 2009. Costs for building them remained in construction-in-progress at September 30, 2009, and will be reclassified once the refinery and pre-treatment plant are fully operational and placed in service.

Additional long-lived assets consist of our two sites in Illinois and Nebraska. The land and improvements are held for development of production facilities.

We evaluate impairment of long-lived assets in accordance with ASC Subtopic 360-10 (formerly SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets.”). We assess the impairment of long-lived assets, including property and equipment and purchased intangibles subject to amortization, when events or changes in circumstances indicate that these assets have been impaired and we accordingly write them down to their new fair value. Forecasts of future cash flows are critical judgments in this process and are based on our experience and knowledge of our operations and the industries in which we operate and are critical to our impairment assessments. These forecasts could be significantly affected by future changes in market conditions, the economic environment, and capital spending decisions of our customers, inflation and our ability to secure additional working capital to allow us to achieve the forecasted results.

With respect to our idle landholdings in Illinois and Nebraska within our North American segment we considered whether these assets were impaired by looking at the undiscounted cash flows compared to our carrying values in accordance with ASC Subtopic 360-10 and concluded that these assets were impaired. As a result, we charged $2,086,350 to expense to recognize the difference between the estimated fair value as determined by management after considering available information including appraisals of the respective properties and the current capitalized carrying value. The determination of estimated future undiscounted cash flows is highly uncertain in the current economic environment. Our estimated undiscounted cash flows considered principally the current value of the underlying land assuming a near-term sale in an orderly market, as well as anticipated cash flows from executing our planned development activities (development of cellulosic ethanol plants). These cash flow estimates, while they represents our best estimate of future undiscounted cash flows, are highly uncertain and could be negatively affected by the continued erosion of the capital markets, availability of capital negating the company’s ability to generate cash flows as planned from the development and operation of ethanol facilities at these locations or forcing the Company to liquidate these assets to generate working capital in a manner that is not consistent with an orderly sale. As of September 30, 2009, the Company has determined that the recent default of loans by the senior lender which could force a liquidation is an indicator of impairment arising since our December 31, 2008 analysis and, accordingly, an asset impairment charge of $2,086,350 has been recorded in the three months ended September 30, 2009. No impairment losses were recorded for the three months ended September 30, 2008. We will continue to assess the factors above and their impact on the cash flow estimates. Upon continued degradation of the economic factors effecting cash flow estimates, knowledge of other prevalent indicators, or actions that we believe would force liquidation, we will reassess the value of these assets in accordance with ASC Subtopic 360-10.

Inventories

Inventories are stated at the lower of cost, using the first-in and first-out (FIFO) method, or market. In assessing the ultimate realization of inventories, we perform a periodic analysis of market prices and compare that to our weighted-average FIFO cost to ensure that our inventories are properly stated at the lower of cost or market

Stock-Based Compensation

Stock-Based Compensation Expense. Effective January 1, 2006, we adopted the fair value recognition provisions of ASC Section 715-20-50 (formerly SFAS No. 123 (Revised 2004), “Share-Based Payment”), requiring us to recognize expense related to the fair value of our stock-based compensation awards adjusted to reflect only those shares that are expected to vest. Our implementation of ASC Section 715-20-50 used the modified-prospective-transition method.



34





We made the following estimates and assumptions in determining fair value of stock options as prescribed by ASC Section 715-20-50:

·

Valuation and Amortization Method — The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing formula and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.

·

Expected Term — The expected term represents the weighted-average period that our stock-based awards are expected to be outstanding. We applied the “Simplified Method” as defined in the Securities and Exchange Commission’s Staff Accounting Bulletin No. 107 and 110.

·

Expected Volatility — The Company’s expected volatility is based on the historical volatility of comparable public companies’ stock for a period consistent with our expected term.

·

Expected Dividend — The Black-Scholes-Merton valuation model calls for a single expected dividend yield as an input. The Company currently pays no dividends and does not expect to pay dividends in the foreseeable future.

·

Risk-Free Interest Rate — The Company bases the risk-free interest rate on the implied yield currently available on United States Treasury zero-coupon issues with an equivalent remaining term.

Recently Issued Accounting Pronouncements

The Company adopted the provisions of ASC 820-10, Fair Value Measurements and Disclosures (formerly SFAS No. 157, Fair Value Measurements), with respect to non-financial assets and liabilities effective January 1, 2009. This pronouncement defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. The adoption of ASC 820-10 did not have an impact on the Company’s consolidated financial statements.

The Company adopted ASC 805 (formerly SFAS No. 141(R), “Business Combinations”) for business combinations. This topic changes the accounting for acquisition transaction costs by requiring them to be expensed in the period incurred, and also changes the accounting for contingent consideration, acquired contingencies and restructuring costs related to an acquisition. The Company also adopted ASC Section 810-10-65, Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51 (formerly SFAS No. 160, “Non-controlling Interests in Consolidated Financial Statements-an amendment of ARB No. 51”). This statement changes the accounting and reporting for minority interests, which are re-characterized as non-controlling interests, classified as a component of equity and accounted for at fair value. ASC 805 and ASC 810-10-65-1 are effective for the Company’s 2009 financial statements. Early adoption is prohibited. The effect the adoption of ASC 805 has had and will have on the Company’s financial statements will depend on the nature and size of acquisitions we complete after adoption. We adopted ASC 810-10-65-1 as of January 1, 2009. As a result, we reclassified the 49% non-controlling interest in our subsidiary Energy Enzymes, Inc., prospectively. Had we continued to apply the prior method of accounting for non-controlling interests, losses incurred by this entity would have been fully attributed to us.

The Company adopted ASC 825-10 (formerly the Financial Accounting Standards Board (FASB) issued Staff Position SFAS 107-1 and Accounting Principles Board (APB) Opinion No. 28-1, “Interim Disclosures about Fair Value of Financial Instruments”). ASC 825-10 amends FASB Statement No. 107, “Disclosures about Fair Values of Financial Instruments,” to require disclosures about fair value of financial instruments in interim financial statements as well as in annual financial statements. APB 28-1 amends APB Opinion No. 28, “Interim Financial Reporting,” to require those disclosures in all interim financial statements. ASC 825-10 is effective for interim periods ending after June 15, 2009. Adoption of this statement did not have a material effect on the Company’s financial statements. See Note 17 Fair Value Measurement.

The Company adopted ASC 320-10 (formerly Staff Position SFAS 115-2 and SFAS 124-2, “Recognition and Presentation of Other-Than-Temporary Impairments”. ASC 320 provides guidance in determining whether impairments in debt securities are other than temporary, and modifies the presentation and disclosures surrounding such instruments. ASC 320 is effective for interim periods ending after June 15, 2009,. Adoption of this statement did not have a material effect on the Company’s financial statements.



35





In June 2009, the FASB issued ASC 105 (formerly SFAS No. 168, "The FASB Accounting Standards Codification (TM) ("Codification") and the Hierarchy of Generally Accepted Accounting Principles - a replacement of FASB Statement No. 162" ("SFAS No. 168"). ASC 105 establishes the Codification as the single official source of authoritative United States accounting and reporting standards for all non-governmental entities (other than guidance issued by the SEC). The Codification changes the referencing and organization on financial standards and is effective for interim and annual periods ending on or after September 15, 2009. ASC 105 is not intended to change the existing accounting guidance, its adoption did not have an impact on our financial statements.

In October, the FASB issued EITF Issue no. 2009-13, Revenue Recognition (Topic 605), Multiple Deliverable Revenue Arrangements, which applies to multiple-deliverable revenue arrangements that are currently within the scope of FASB ASC 605-25 (previously included in EITF Issue no. 00-21, Revenue Arrangements with Multiple Deliverables). The EITF will be effective on a prospective basis for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. The Company has not fully assessed the impact of this guidance, but at this time believes it will not have an impact on our financial statements.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk.

We are exposed to various market risks, including changes in commodity prices and foreign currency exchange rates. Market risk is the potential loss arising from adverse changes in market rates and prices.

Commodity Risk

We are subject to market risk with respect to the price and availability of refined palm oil and palm stearin, the principal raw materials we use to produce biodiesel and biodiesel by-products. In general, rising feedstock prices result in lower profit margins and, therefore, represent unfavorable market conditions. This is especially true when market conditions do not allow us to pass along increased feedstock costs to our customers. The availability and price of feedstock for our biodiesel plant is subject to wide fluctuations due to unpredictable factors such as weather conditions, governmental policies with respect to agriculture and international trade, and global demand and supply.

At September 30, 2009 we did not have any firm-price purchase commitments with our feedstock suppliers or off-take arrangements with our customers.

Foreign Currency Risk

Our foreign subsidiaries use local currencies as their functional currency. Our primary exposure with respect to foreign currency exchange rate risk is the change in the dollar/INR (Indian rupee) exchange rate. For consolidation purposes, assets and liabilities are translated at month-end exchange rates. Items of income and expense are translated at average exchange rates. Translation gains and losses are not included in determining net income (loss) but are accumulated as a separate component of shareholders’ equity. Gains (losses) arising from foreign currency transactions are included in determining net income (loss). During the three months ended September 30, 2009, we recognized a gain of $180,250 arising from foreign currency translation. At September 30, 2009 we did not have any outstanding derivative financial instruments, off-balance sheet guarantees, interest rate swap transactions or foreign currency contracts.

Interest Rate Risk

Our market risk is also affected by changes in interest rates. At September 30, 2009, we had $13,997,541 in total debt outstanding, of which $9,828,417 was fixed-rate debt and $4,104,457 was floating-rate debt. The interest rate under this facility is subject to adjustment based on the Reserve Bank of India advance rate.

Based on the amount of our floating-rate debt as of September 30, 2009, each 100 basis point increase or decrease in interest rates increases or decreases our annual interest expense and cash outlay by approximately $41,000. This potential increase or decrease is based on the simplified assumption that the level of floating-rate debt remains constant with an immediate across-the-board increase or decrease as of September 30, 2009 with no subsequent change in rates for the remainder of the period.



36





Item 4.

Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”). Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered in this report, as a result of the matters discussed below, with respect to our internal control over financial reporting, our disclosure controls and procedures were not effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Controls over Financial Reporting

As of December 31, 2008, we concluded that we had a material weakness in our internal controls over financial reporting with respect to financial reporting at the India subsidiary as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2008. During the three and nine month periods ended September 30, 2009 we implemented processes to remediate this material weakness by identifying and defining non-routine and complex transactions on a regular basis and by researching, identifying, analyzing, documenting, and reviewing applicable accounting principles. The Company believes that these corrective actions, taken as a whole, will remediate the control deficiencies identified above, but the Company will continue to monitor the effectiveness of these actions and will make any other changes or take such other actions as management determines to be appropriate. Other than the implementation of the remediation measures described above, there have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the period covered by this report that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

Inherent Limitations on the Effectiveness of Controls

Our management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Our controls and procedures are designed to provide reasonable assurance that our control system’s objective will be met and our CEO and CFO have concluded that our disclosure controls and procedures are effective at the reasonable assurance level. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of the effectiveness of controls in future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.



37





PART II -- OTHER INFORMATION

Item 1.

Legal Proceedings

On March 28, 2008, the Cordillera Fund, L.P. ("Cordillera") filed a complaint in the Clark County District Court of the State of Nevada against American Ethanol, Inc. and the Company. The complaint seeks a judicial declaration that Cordillera has a right to payment from the Company for its American Ethanol shares at fair market value pursuant to Nevada's Dissenters' Rights Statute, a judicial declaration that Cordillera is not a holder of Series B preferred stock in the Company under the provisions of the statute; and a permanent injunction compelling the Company to apply the Dissenters' Rights Statute to Cordillera's shares and reimburse Cordillera for attorneys fees and costs. On or about October 7, 2009, the Court entered a judgment awarding damages to Cordillera for the fair market value of the shares of stock plus accrued interest at the statutory rate of 5% from the date of merger. The time to appeal this decision has not yet run.

On May 1, 2009 our transfer agent, Corporate Stock Transfer, Inc. (“CST”), filed a Complaint for Interpleader in the United States District Court for the District of Colorado. The interpleader action is based on the Company’s and CST’s refusal to remove the restrictive legend from a certificate representing 5,600,000 shares of the Company's restricted common stock (the “Certificate”) held by Defendant Surendra Ajjarapu and seeks a judicial determination as to whether the legend can be lawfully removed from the Certificate. On July 1, 2009 Defendant Ajjarapu answered the Complaint for Interpleader, and Cross-Claimants and Counter-Claimants Surendra Ajjarapu and Sandhya Ajjarapu (the “Ajjarapus”) cross-claimed against the Company for breach of fiduciary duty, conversion, violation of Section 10(b) of the Exchange Act and Rule 10b-5 and injunctive relief. The Ajjarapus also counter-claimed against CST for declaratory judgment The Company does not believe it has any liability for the matters described in this litigation and intends to defend itself vigorously. However, there can be no assurance regarding the outcome of the litigation. An estimate of possible loss, if any, or the range of loss cannot be made and therefore we have not accrued a loss contingency related to these actions.

Item 1A.

Risk Factors.

No change in risk factors since the Company’s Annual Report on Form 10-K filed with SEC on May 15, 2009.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3.

Defaults On Senior Securities.

No additional defaults on senior securities other than those reported in the Companies current report on Form 8-K filed with the SEC on August 17, 2009 and October 13, 2009.

Item 4.

Submission of Matters to a Vote of Security Holders.

None

Item 5.

Other Information.

In the quarter ended September 30, 2009, the Company determined to impair the value of two parcels of land it previously acquired in Nebraska and Illinois with a view to development of ethanol facilities. As a result, the Company incurred a non-cash charge of $2,086,350. The Company believes that in light of the default on the senior debt facility and the collateralization of these properties under the term of the loan agreement, as well as the challenging global economic conditions, the Company is required to reevaluate the potential future development of these properties. The impairment charge is the difference between the estimated fair value as determined by management after considering available information including appraisals of the respective properties and the current capitalized carrying value. The decision to impair the identified land parcels was approved by a committee of the Company’s Board of Directors on November 5, 2009. The charges are not currently expected to result in additional material future cash expenditures.



38





Item 6.

Exhibits.

 

 

31.1

Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes- Oxley Act of 2002.

32.1

Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.




39





SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


 

AE BIOFUELS, INC.

 

 

 

 

 

 

 

By:

/s/ ERIC A. MCAFEE

 

 

Eric A. McAfee

Chief Executive Officer

(Principal Executive Officer)

 

 


Date: November 5, 2009



40